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ABSTRACT
Background: Measles is a highly contagious disease that mainly affects children and according to 
the World Health Organisation (WHO), was responsible for over 164000 deaths in 2008,  despite 
the availability of a safe and cost-effective vaccine [56]. The Measles virus (MV) inactivates T-
cells, rendering them dysfunctional, and results in virally induced immunosuppression which shares 
certain features with that induced by HIV. Targets as well as genetic markers distinctive to the MV 
and common to both (Measles and HIV) have not yet been defined. The MV targets the PI3K/AKT 
pathway which is involved in a number of cellular processes such as cell growth, proliferation and 
survival. The MV interferes with the signalling of the pathway and results in the production of 
alternatively spliced protein isoforms such as the  SIP110, an alternatively spliced isoform of the 
phosphatase SHIP145, which was shown to directly inhibit T cells [50]. The aim of this project was 
to determine whether more of these types of alternatively spliced isoforms exist, and could thus be 
potential genetic markers of T cell suppression.
Methods: A GeneChip Exon array analysis was performed on RNAs isolated from human T cells. 
In parallel, splicing targets that may be affected by PI3K were identified through the use of publicly 
available  databases  such  as  Genecards  and  Entrez.  Microarray  datasets  from  GEO  and 
ArrayExpress as well as transcript data from dbEST and alternative splicing data from Ensembl and 
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Genecards were used to support the identified splicing targets. Functional pathway analysis was 
performed using DAVID for functional clustering and the KEGG Mapper for pathway mapping. 
InterProScan was used for the protein functionality of the identified isoforms [65], and protein-
protein interaction were determined using the STRING database [62].
Results: The  genes  ATM,  CALD1,  LCK,  VCL,  PRMT5,  NRP1 and  MXI1 were found to  show 
different transcripts  under normal versus T cell  suppression conditions.  ATM, PRMT5 and  VCL 
overlapped with the differentially regulated list from the GeneChip exon array whilst CALD1, LCK, 
NRP1 and MXI1 overlapped with the alternatively spliced list. Functional pathway analysis showed 
MXI1 is involved in DNA binding and has transcription repressor activity as well as implications in 
neurofibrosarcoma and prostate cancer. CALD1 plays a role in vascular muscle contraction, LCK is 
involved in natural killer cell mediated cytotoxicity and the T cell receptor signalling pathway, ATM 
is involved in apoptosis and plays a role in the p53 signalling pathway,  VCL is involved in focal 
adhesion and regulates the actin cytoskeleton, PRMT5 forms part of the RNA transport pathway and 
NRP1 is involved in axon guidance and has been shown to regulate T cell activation at the immune 
synapse. Low levels of LCK have been implicated in severe combined immunodeficiency (SCID) 
whilst  ATM is  part  of  a  range of cancers including breast  cancer,  lymphoma as  well  as ataxia 
telangiectasia. For some of the genes whose transcripts were found to be expressed under T cell  
suppression conditions, the biotype was retained introns (ATM and CALD1) and nonsense-mediated 
decay (CALD1 and PRMT5), which is the same biotype as the SIP110. Using InterProScan it was 
determined that protein-coding transcripts found under T cell suppression conditions, seem to lack 
the protein kinase-like domains and suffered from a loss of conserved motifs that are present in their 
counterparts  expressed  in  normal  conditions.  The  protein-protein  interaction  analysis,  using 
STRING,  showed  that  the  T  cell  suppressed  isoforms  of  LCK have  relationships  with  genes 
involved in T cell activation, T cell antigen receptor mediated signalling, T cell mediated killing and 
assembly and expression of the T cell receptor (TCR). Isoforms identified for  NRP1 under T cell 
suppression conditions had relationships with genes involved in the cell cycle. 
Conclusion:  Although  challenges  to  the  study included lack  of  proper  annotated  EST/cDNAs, 
weaknesses to the GEO2R and limitations of the interaction tool STRING, potential biomarkers for 
T cell suppression were identified for ATM, CALD1, LCK, VCL, PRMT5, NRP1 and MXI1. It was 
discovered that isoforms found expressed under T cell suppression conditions lacked the protein 
kinase-like domain and some conserved motifs. Interestingly the proline-rich regions seem to be the 
'housekeepers'  for the isoforms, as the regions were found conserved in the isoforms expressed 
under  both  conditions,  the  normal  and  T  cell  suppression.  Further  studies  would  need  to  be 
performed in order to better understand how the T cell suppressed isoforms affect the relationships 
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and  an analysis of alternative splicing on the protein interactions.
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CHAPTER 1
LITERATURE REVIEW
When the first draft of the Human Genome Project was published in February 2001, researchers 
were amazed by the findings. The number of human genes appeared to be significantly fewer than 
the previously thought range of 50,000 -  140,000 genes [6]. The project revealed that the human 
genome consists of about 30,000 – 40,000 protein-coding genes, only twice as much as the fruit fly 
[6] but was much more complex with alternative splicing thought to be responsible for generating a 
lot more protein products. Aberrations in alternative splicing have been implicated in a variety of 
diseases with large scale studies having been done into biomarkers, using the alternatively spliced 
products, to distinguish between normal and diseased cells [59].
1.1 Splicing
Splicing is a process whereby introns are removed from the pre-mRNA and exons joined to form a 
mature  mRNA (Figure  1.1).  The  reaction  occurs  in  the  nucleus  co-  or  post-transcriptionally 
resulting in the mRNA being exported to the cytoplasm for translation into protein products [1].
Figure 1.1: The catalytic steps of the nuclear pre-mRNA splicing. Exons are shown as boxes and  
introns as lines. Step 1 sees the detached 5' exon and an intron/3' exon fragment forming a 
lariat structure. Step 2 is the ligation of the two exons and the release of the intron lariat to form  
a mature mRNA [1,3]. 
branch point 3' splice site5' splice site
Step 1
Step 2
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Exons make up one tenth of an average pre-mRNA and recognition is tantamount to looking for a  
needle (exons) in a haystack (introns) [2]. Precision during splicing is very important in order to 
avoid costly mistakes that can affect the protein-coding ability of a gene [2]. 
The recognition of the 5' and 3' splice sites of the pre-mRNA is possible due to the presence of the 
AGGURAGU and  the YAG sequences respectively and are limited to  the exon/intron borders 
allowing for the recognition and the excision of introns from the pre-mRNA [1]. A third sequence 
YNCURAY, called the branch point, is found 18-30 nucleotides upstream of the 3' splice site and 
allows for the release of the intron post excision (Figure 1.1). The splicing reaction is made possible 
by the presence of a spliceosome which is a large macromolecular complex that binds onto the 
aforementioned  sequences  [3].  The  spliceosome  is  made  up  of  five  small  ribonucleoproteins 
(snRNP) that recognise the splice sites and are responsible for the removal of the introns (Figure 
1.2).
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Although the three sequences are necessary for the splicing process,  they are not sufficient.  In 
addition to the splice site sequences, other splicing regulatory elements (SREs) aid the splicing 
process.  The SREs are classified as exonic splicing enhancers (ESEs) or silencers (ESSs) if they 
promote or inhibit the inclusion of the exon where they reside, and as intronic splicing enhancers 
(ISEs) or silencers (ISSs) if they enhance or inhibit the inclusion of the exon adjacent to the intron 
where they reside (Figure 1.3) [4].
Figure 1.2: The spliceosome complex contains five small nuclear ribonucleoproteins (snRNP) that  
assemble onto the intron. The complex E contains the U1 snRNP bound to the 5' splice site. The 
branch point is bound by SF1, the polypyrimidine tract by U2AF 65 and the AG dinucleotide by  
U2AF 35 as well  as the unbound U2 snRNP. When U2 attaches to  the branch point via the  
RNA/RNA base-pairing, complex A is formed. Complex B is formed when complex A is joined by  
the  U4/5/6  tri-snRNP.  The  interactions  of  the  U1  and  U4  snRNPs  are  lost  during  the  
rearrangement of complex B to form the catalytic complex C. The formation of complex C results  
in splicing [51]. 
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The enhancer elements are bound by positive regulators (SR) whilst silencer elements are bound by 
negative regulators (hnRNP) as illustrated in Figure 1.3 above. An example of a positive regulator is 
the SR protein family that contains more than one RNA binding domain as well as a serine/arginine-
rich domain whilst the hnRNP proteins are an example of a negative regulator [2]. A fine balance 
between  the  regulators  is  necessary  for  contr lling  the  level  of  exon  inclusion  in  the  mRNA 
transcript [2,5].
As mentioned previously,  the first  draft  of the Human Genome Project revealed a  much lower 
number of protein-coding genes than expected, and alternative splicing is thought to be responsible 
for generating a larger diversity of protein products.
Figure 1.3: Splicing regulatory elements (SRE) . The exonic splicing enhancer (ESE) and intronic  
splicing enhancer (ISE) are bound by the positive regulator, the SR proteins whilst the exonic  
splicing silencers and intronic splicing silencers are bound by the negative regulator, the hnRNP  
proteins [51].
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1.2 Alternative splicing
Alternative splicing is the differential removal of exons from mature mRNA or the inclusion of 
intronic sequences. One gene can produce many protein products partially explaining the genome 
complexity of  eukaryotes  (Figure 1.4).  It  is  now believed that  up to 94% of human genes  are 
alternatively spliced and that splicing is affected by an estimated 50% of disease causing mutations 
[2].
 
As  illustrated  in  Figure  1.5  below,  different  combinations  of  exons  can  be  spliced  together  to 
produce different mRNA isoforms of a gene that encode not only structurally different but also 
functionally different protein products [7].
Figure 1.4: Alternative splicing. The process can produce many protein products that are not only  
structurally different but performs various functions too, all derived from a single mRNA [46].
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 Most exons are constitutive as they are always spliced or included in the final mRNA product, there 
is no alternative splicing [3]. The most common type of alternative splicing event is the cassette 
exon whereby the regulated exon is sometimes included or excluded from the mRNA (Figure 1.5: 
2). Multiple cassette exons are what are termed mutually exclusive exons (Figure 1.5: 6), whereby 
mRNAs consisting of one of several possible exon choices are produced [3]. Alternative 5' and 3' 
splice sites (Figure 1.5: 3 and 4) r sults in the lengthening or shortening of a particular exon whilst 
alternative promoters (Figure 1.5: 1) and alternative polyadenylation sites switch the 5' and 3' exons 
of a transcript (Figure 1.5: 7 and 8). 
A normal protein-coding human gene has on average 8.8 exons which are usually short in length 
(10  to  400  nt),  whilst  introns  are  usually  10  times  or  more  the  length  of  the  exons  (200,000 
nucleotides or more) [1,8]. Exons have always been and are known to have coding ability whilst 
introns used to be referred to as 'junk DNA' (non-coding DNA)[9]. Some introns are now known to 
have coding ability, but at a much smaller scale than exons [1]. As an example, introns have been 
shown to play roles in gene regulation via alternative splicing as well  as in nonsense-mediated 
decay (NMD) [10-12]. When introns are retained within an mRNA (Figure 1.5: 5), in frame stop-
codons are usually introduced and prematurely terminated proteins are translated resulting in NMD 
[1]. NMD thus functions to  down-regulate  gene expression.  Barash et  al  (2010) noticed that  a 
certain class of alternative exons that introduce a premature termination codon (PTC) and activate 
Figure 1.5: Different types of alternative splicing events [48]. 1. Alternative promoter 2. Cassette  
exon 3. Alternative 5' splice sites 4. Alternative 3' splice sites 5. Intron retention 6. Mutually  
exclusive 7. and 8. alternative terminal exons.
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NMD, are found in adult  tissues and suppress mRNA expression but are skipped in embryonic 
tissues  resulting  in  mRNA expression  [10].  Some  introns  have  been  shown  to  enhance  gene 
expression, known as intron-mediated enhancement (IME) and are found to occur amongst humans, 
plants, insects and mice [13].
1.2.1 Regulation of alternative splicing
Studies have demonstrated that cells frequently regulate alternative splicing events in response to 
external stimuli, cell type, developmental stage and gender [8]. The SREs (see the splicing section) 
function to regulate alternative splicing by enhancing (ESEs and ISEs) or silencing (ESSs and ISSs) 
splicing (Figure 1.3). In addition to these SREs, RNA binding proteins belonging to the SR protein 
and the hnRNPs families are known to promote and inhibit splicing respectively (Figure 1.6) [14]. 
Changes in  splice site selection are influenced by phosphorylation events that  are  regulated by 
known  signal  transduction  pathways  and  the  SR-proteins  are  known  to  be  phosphorylated  by 
several kinases such as the cdc2 like kinases and Clk1-4  [8]. Phosphorylation of the SR-protein 
SF2/ASF  increases  its  binding  to  the  U1  70K  snRNP  promoting  exon  inclusion [8].  The 
phosphorylation is reversed by phosphatases such as protein phosphatase 1 (PP1), PP2A and protein 
phosphatase 2Cgamma and the complete blocking of these inhibits splicing as dephosphorylation is 
necessary for the transesterification step (Figure 1.2)  [8]. Both in vitro and in vivo studies have 
shown  that  changing  levels  of  the  phosphatase  has  an  influence  on  alternative  exon  usage 
suggesting that phosphatases can be used by cells to regulate alternative splicing [8].
A lesser  known topic  of  the  splicing  regulatory  mechanisms are  the  impact  of  the  pre-mRNA 
structures on alternative splicing. This very topic has been reviewed by McManus, C.J. et al (2011) 
and  they  demonstrate  that  these  pre-mRNA structures  (both  local  and  long-range  structures) 
regulate alternative splicing preventing the 5' and 3' splice site recognition by the spliceosome [14]. 
Figure 1.6: The sequences and proteins involved in alternative splicing. In addition to the SREs, SR 
proteins and hnRNPs are known to promote and inhibit splicing respectively [14].
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Over the past few years, literature has provided a link  between aberrant alternative splicing and 
different  aspects  of  human  diseases  with  the  association  mostly  between  splicing  variants  and 
cancer [15].
1.2.2 Alternative splicing and disease
The  regulatory  elements  mentioned  above  can  be  altered  and  cause  aberrant  regulation  of 
alternative splicing with the changes manifesting as disease. Mutations that affect splicing can cause 
disease directly or contribute to the susceptibility or severity of disease [2]. See Table 1.1 for some 
examples.  Changes in  splicing  patterns  associated  with  many  cancers  are  important  in  the 
transformation, motility and metastasis of the tumour tissue [16]. In the case of cancers, alternative 
splicing is known to affect hormonal signalling, apoptosis as well as cell -cell or matrix interactions 
[8,16]. 
Examples of abnormally spliced genes detected in cancers include  CD44,  MUC2,  SRF,  NCAM, 
MLH, MSH as well as members of the Wnt pathway [16]. These genes may be used as markers of 
the diseases or as drug targets but limited larger clinical trials as well as factors such as individual 
patient differences, tissue complexity and lack of tools pose some challenges [16]. 
Table 1.1: Examples of disease causing mutations related to splicing
Mutation Disease Gene Involved Type of Mutation Mutation effect Symptoms
Intron  mutations 
that  alter  splice-
site recognition
Familial 
Dysautonomia 
(FD)
IKBKAP  gene, 
coding for IKAP
A  silent  T  to  C 
transition in the 6th 
base of the intron 
leads  to  skipping 
of exon 20 
Introducing a PTC 
resulting in NMD 
of the mRNA and 
decreased 
expression  of 
IKAP
It's  a  disorder  of 
the  autonomic 
nervous  system. 
Patients  are 
insensitive to pain, 
unable to produce 
tears, poor growth
Exon  mutations 
that  disrupt 
splicing
Spinal  muscular 
atrophy (SMA)
Survival  motor 
neuron  (SMN) 
protein  encodes 
for  SMN1  and 
SMN2
SMN2  can't 
compensate due to 
a  silent  C  to  T 
substitution in the 
6th nucleotide  of 
exon 7 resulting in 
exon skipping
Production  of  a 
truncated, inactive 
protein 
Infant  mortality 
and  motor  neuron 
degeneration 
resulting  in 
progressive 
paralysis
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Mutation Disease Gene Involved Type of Mutation Mutation effect Symptoms
Splicing  as  a 
genetic  modifier 
of disease
Menkes  disease 
(MD)  and 
occipital  horn 
syndrome (OHS) 
ATP7A  gene, 
encodes a copper-
transporting 
ATPase
Mutations  in  the 
invariant 
dinucleotides  at 
the 5 and 3 splice 
sites  eliminate 
exon  recognition 
cause  MD  whilst 
OHS  is  due  to 
mutations 
occuring  in  the 
less  conserved 
regions
With  MD,  the 
expression  of  the 
correct  splice 
variant  is 
drastically 
reduced  or  even 
eliminated.
With  OHS,  the 
splice variants are 
still produced.
neurological 
degeneration, 
connective  tissue 
defects, distinctive 
kinky  and  brittle 
hair  as  well  as 
early-childhood 
death
Mutations  that 
alter  the  ratio  of 
alternatively 
spliced isoforms
Frontotemporal 
dementia  and 
Parkinsonism 
linked  to 
chromosome  17 
(FDTP-17)
MAPT  gene 
encodes for tau, a 
protein  involved 
in  microtubule 
assembly  and 
stability
Mutations  in 
exon10  alter  the 
ratio  of  tau 
isoform 
containing  either 
3R  or  4R  repeat 
microtubule 
binding sequences
Mutations  in 
exon10  alter  the 
ratio  of  tau 
isoform 
containing  either 
3R  or  4R  repeat 
microtubule 
binding sequences
Difficulty 
walking,  rigidity, 
tremor  or  muscle 
weakness, 
difficulty  naming 
familiar objects
Mutations  in 
regulators  of 
alternative 
splicing
Amyotrophic 
lateral  sclerosis 
(ALS)
TDP-43 Protein 
abnormally 
included  in 
ubiquitinated 
protein aggregates 
Unstable 
nucleotide  repeat 
expansions
Myotonic 
dystrophy (DM)
DMPK and ZNF9 
genes
DMI  is  due  to  a 
CTG trinucleotide 
expansion in the 3 
UTR  of  the 
DMPK  gene. 
DM2  is  due  to  a 
CCTG 
tetranucleotide 
expansion  within 
the  first  intron  of 
the ZNF9 gene 
Skeletal  muscle 
wasting, cataracts, 
myotonia,  insulin 
resistance
The abnormally spliced genes are usually not mutated but the defects are as a result of a change in 
the nuclear environment that regulates splice site choice [2]. 
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1.2.3 Approaches to detection of alternative splicing 
Several  approaches  have  been  developed  or  used  over  the  years  to  study  alternative  splicing. 
Techniques such as microarrays, high-throughput sequencing analysis, and ESTs have all been used 
with varying degrees of success to understand alternative splicing.
1.2.3.1 Expressed sequence tags (ESTs)
Several genome-wide studies for computational detection of alternative splicing, using expressed 
sequence tags (EST) have been carried out over the past decade [17-22]. ESTs are 'single-pass' 
cDNA sequences (~360bp) and are a rich source of information for understanding gene expression 
and structure (Figure 1.7).
Earlier studies have relied heavily on ESTs to study alternative splicing as they represent a wide 
variety of different tissue types both diseased and normal as well as immortalised cell lines whilst  
providing a 'snap-shot' of human development (from embryos to late adulthood) [19]. ESTs are also 
important in gene discovery, genome annotation, gene structure identification, characterization of 
Figure 1.7: Expressed Sequence Tags (EST) are short (200-800 nt) and single-pass sequences  
derived from cDNA libraries. RNA is reverse transcribed to a double-stranded cDNA using  
reverse  transcriptase.  The  cDNA  is  then  cloned  and  randomly  sequenced  from  both  
directions in a single-pass run to obtain 5' and 3' ESTs [23].
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splice variants, SNP data mining as well as proteome analysis [23]. Accessibility is also one of the 
major reasons why ESTs are still popular for examining alternative splicing. They are accessible 
from public databases such as the GenBank dbEST. As of the 1st January 2012, the organism with 
the highest number of EST entries was Homo sapiens at  8,315,294 followed by Mus musculus at 
4,853,562 [52]. 
Although ESTs provide an ideal tool for alternative splicing detection, this is not without challenges 
or  problems.  Studies  of  alternative  splicing  using  ESTs  are  hampered  by  protocol  differences, 
transcript end bias, and library coverage limitations (Table 1.2) [24].
 
Table 1.2: Issues with high-throughput alternative splice detection [22]
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When trying to identify alternatively spliced isoforms, ESTs from the same gene are searched for 
differences that are consistent with alternative splicing, for example a large insertion or a deletion 
(Figure 1.8). Each candidate splice product can be further assessed by mapping the ESTs exactly to 
their gene  sequence in the draft genome [22].
1.2.3.2 Microarrays
The role that microarrays play in detecting splicing events was suggested as early as 2000 [24,25]. 
Exon  microarray  technology  enables  genome-wide  quantification  of  expression  levels  of  the 
majority  of exons and helps in  detecting alternatively spliced isoforms  [26].  The most  popular 
method to detect alternative splicing is the Splicing Index (SI), which identifies exons that have 
different inclusion rates relative to the gene level, between two groups [26,53]. An SI of 0 indicates 
equal inclusion rates of the exon in both samples, positive values indicate enrichment of that exon 
in Sample 1,  and negative values indicate  repression or  exon skipping in  Sample 1 relative to 
Sample 2 [53]. 
Figure 1.8: Computational identification of alternative splicing. a,  insertion and deletion in ESTs  
relative to mRNA are identified as potential alternative splices. b, splice products are identified  
and intronic splice junction donor and acceptor sites are checked. Alternative splice products are  
detected when two exons are mutually exclusive [22].
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
23
There are different types of microarrays. The  3' expression microarrays are the earliest forms of 
microarrays and are used to approximate the expression of the entire gene. This approach assumes 
that the 3' end of a gene is clearly defined, has an intact poly-A tail and that the entire length of the 
gene  is  expressed  as  a  single  unit  [54].  This  type  of  microarray  doesn't  discriminate  between 
alternatively spliced transcripts that have identical 3' ends; transcripts lacking a 3' exon because of 
alternative splicing, or non-polyadenylation, and genomic deletions etc., are not detected in the 3' 
based expression experiments [54].
The exon microarrays on the other hand, such as the Affymetrix Human Exon 1.0 ST Array, are 
used to detect alternative splicing.  The microarray platform contains probes for 80%   of human 
exons and detects differential use of specific exons and allows one to distinguish between different 
splice variants, to quantify expression levels for exons and genes [2,26]. 
1.2.3.4 Next generation sequencing
RNA Sequencing (RNA-Seq), like ESTs, are generated from cDNAs but are different as they are 
sequenced using high-throughput Illumina or other next generation sequencing technologies and are 
then used to define exons, 5' and 3' boundaries and introns as well as gene expression levels [27]. 
An advantage of using RNA-Seq is that RNAs expressed at very low levels can be detected and 
quantified.
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1.3 T cell silencers
The immune system of a healthy organism maintains immune balance between tolerance and active 
response. Under normal physiological conditions, the immune balance is a tightly regulated network 
of several types of immune cells. If this is disturbed, the response can be either inefficient (as in  
cancer)  or,  conversely,  over-reactive,  resulting  in  conditions  such  as  autoimmunity  [28]. 
Maintaining immune tolerance is vital for organ transplantation and T cells play an important role 
in determining whether the organ gets rejected or not [29]. Various studies on organ transplantation 
[29] target T cells and have demonstrated that suppression of the T cells is important in maintaining 
immune tolerance.  VSIG4, a member of the B7 family-related proteins, was identified as a T cell 
silencer [30] whilst dendritic cells transfected with hVSIG4 recombinant adenovirus and shown to 
cause  T cell  suppression,  was  suggested  as  a  way of  maintaining  immune tolerance  for  organ 
transplantation or autoimmune diseases [31]. Another T cell silencer that has been identified is the 
B7-H1 or PD-L1 (a B7 member), a PD-1 ligand [32,33].
A multitude of pathogens that cause infections often result in the immune system being suppressed. 
The  Measles  Virus  (MV)  and  the  Human  Immunodeficiency  Virus  (HIV)  are  such  pathogens 
[34,35].  In  Vienna,  von  Pirquet  first  described  measles  virus-induced  immunosuppression  as 
represented by the disappearance of delayed-type hypersensitivity (DTH) skin test  responses to 
tuberculin in 1908. His work with measles virus provided the first evidence that viruses have the 
ability  to  suppress  the  immune  system  [55].  In  this  section,  the  MV  is  used  to  illustrate  
immunosuppression but do note that MV resembles  HIV in many aspects except for being less 
severe and its spontaneous reversibility [36].
MV belongs  to  the  family  Paramyxoviridae, subfamily  Paramyxovirinae, genus  Morbillivirus.  
Other members of the Morbillivirus genus, specifically canine distemper virus and rinderpest virus, 
have also been shown to cause immunosuppression [37,38].  Even though the highly contagious 
measles  virus  is  contracted  once  in  a  lifetime  and  is  vaccine-preventable,  more  than  350  000 
children  succumb  to  the  disease  annually  [35,56].  Symptoms  of  the  infection  include  rash, 
conjuctivitis,  fever  and  lethal  complications  due  to  its  suppressive  nature  and  results  in 
opportunistic infections such as pneumonia and encephalitis [35,36].
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The virus causes infection by entering the respiratory tract mucosa of the host by droplets or aerosol 
dispersion and replicates in both the upper and lower respiratory tracts. The virus then spreads to 
the lymph nodes entering the bloodstream and then spreads to multiple organs such as the skin, 
gastrointestinal tract, liver, central nervous system and the thymus (Figure 1.9A)  [39]. The virus 
replicates mainly in the epithelial and endothelial cells of blood vessels, in organs, in macrophages, 
and  monocytes [36,39]. 
During the acute phase of infection, high IFN-γ concentrations aid in viral clearance (Figure 1.9D). 
Cytokines  IL-4  and  IL-10's  concentrations  (secreted  by  CD4+  T cells)  that  are  crucial  in  the 
Figure 1.9: Schematic diagram of the pathogenesis of measles from virus infection to recovery.  
A:The measles-virus infects the respiratory tract and then spreads to the other organs.  B:  
Symptoms include fever, cough and rash that begins when the virus starts clearing.  C: The 
CD8+ and CD4+ T cells appear at the same with the CD4+ T cell activation being prolonged.  
The measles-virus specific IgM is used as a marker for diagnosing measles. During the acute  
disease  and post  recovery,  the  immune system remains  suppressed.  D:  The  production  of  
cytokines aid in viral clearance (IFN-γ) as well as developing antibodies (IL-4 and IL-10)  
[39].
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development  of  antibodies,  increase once the infection has  been brought  under  control  (Figure 
1.9D) [36,39]. After the measles virus infection, MV-induced immunosuppression occurs due to a 
delayed-type  hypersensitivity response to antigens such as tuberculin (initially described by von 
Pirquet) [39]. 
The MV glycoprotein complex made up of the fusion and hemagglutinin proteins actively silence T 
cells  by interfering with signalling pathways essential  for T cell  activation  [35].  The signalling 
pathway targeted by MV is the phosphatidyl-inositol-3-kinase (PI3K)/AKT kinase pathway in T 
cells. The pathway is important in a number of cellular processes such as cell growth, proliferation 
and survival and interference of the signalling by MV results in the arrest of the cell cycle in T 
lymphocytes leading to T cell suppression.
PI3Ks are lipid kinases comprising 8 members that are further divided into 3 classes, based on 
sequence homology, substrate preference and tissue distribution (Table 1.3) [40,41].
The class I PI3K kinases are the most frequently implicated in cancer  [41]. The p110α and it's 
regulatory  subunit  p85  (it  binds  and  inhibits  the  p110α)  are  mostly  involved  in  cell  division 
regulation and tumorigenesis whilst the p110 β, δ, and γ have no known oncogenic mutations [40]. 
The  p110α and the p85 both consist of 5 domains: the p110α, which is encoded by the PIK3CA 
gene, has a kinase with a C-terminal domain, an adaptor binding domain that joins the kinase, a 
Table 1.3: PI3K family members [41]
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Ras-binding domain (RBD), a C2 domain that joins the p85 subunit and a helical domain. The p85's 
domains include the N-terminal Src homology-2 (SH2) and the inter-SH2 domains [40].
AKT is a serine-threonine kinase consisting of 3 family members namely, Akt1, 2 and 3 which are 
encoded by AKT1, AKT2 and AKT3 respectively and are a crucial downstream effectors of PI3K.
Under  normal  physiological  conditions,  when  the  PI3K  is  activated,  AKT phosphorylates  and 
regulates the activity of a number of targets that includes kinases, transcription factors and other 
regulatory molecules  [41]. Through this phosphorylation, AKT regulates a host of cell functions 
such as glucose metabolism, cell proliferation as well as cell survival [41].
The signalling cascade is  usually activated by tyrosine-kinase receptors such as the insulin-like 
growth factor-1 (IGF-1) on the T-cells and is responsible for activating the PI3K. The PI3K, i.e. the 
p110α, phosphorylates  the  phosphatidylinositol-4,5-biphosphate  (PIP2)  to  produce 
phosphatidylinositol  3,4,5-triphosphate  (PIP3).  The  tumor  suppressor  phosphatase  and  tensin 
homolog deleted on chromosome 10 (PTEN) and p110β acts as an antagonist and dephosphoryates 
PIP3  to  PIP2  thus  terminating  PI3K-dependent  signalling  [41].  PIP3  functions  to  bring  the 
phosphoinositide-dependent kinase 1 (PDK1) and AKT, into close proximity which results in PDK1 
phosphorylating and activating AKT, which in turn phosphorylates and activates downstream target 
proteins that are important in different cellular functions (Figure 1.10).
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
28
1.4 Alternative splicing and virally-induced immunosuppression
According to  [35],  the MV is  the only pathogen known to interfere  with the  activation  of  the 
pathway  in  a  contact-dependent  manner.  Figure  1.11  illustrates  what  happens  when  the  MV 
interferes with the PI3K/AKT pathway.
Figure 1.10: PI3K/AKT pathway under normal conditions [41]. Post activation, the PI3K 
phosphorylates AKT which in turn activates downstream targets that play an important  
role in cellular functions.
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The virus prevents the degradation of the Cbl-b proteins which results in the accumulation of PIP3 
thus preventing the activation of Akt kinase. This in turn results in downstream targets such as  
forkhead transcription factors as well as splice regulatory proteins (SR) not being phosphorylated. 
Studies have shown that splice isoforms get produced due to the unphosphorylated splice regulatory 
proteins. One such isoform is the SIP110 which is a product of the lipid phosphatase SHIP145 [35]. 
PIP3 formation is reduced by the presence of the SIP110 resulting in the threshold level of T cell 
activation being increased, leading to T cell suppression [35].
Figure 1.11: MV interferes with the PI3K/AKT signalling pathway [35]. The interference is as a  
result of the MV preventing degradation of the Cbl-b protein which in turn stops the PIP3 from 
activating AKT. As a result downstream targets end up not getting phosphorylated.
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1.5 Problem Identification
1.5.1 Developing biomarkers for T cell suppression
At present, serology is the most common method of confirming measles infection in the laboratory 
[39]. The measles specific antibody, IgM, is usually used to diagnose measles but is detectable only 
4 days or more after a rash manifests and falls to undetectable concentrations within 4-8 weeks of  
rash onset [39]. A point of care diagnostic test for measles is needed similar to the rapid diagnostic 
test for malaria which ideally could be done with oral fluid samples [39]. 
As an estimated 94% of human genes undergo alternative splicing it is important to know which 
spliced variants are expressed, their relative abundance as well as their biological function in order 
to understand a gene's function under normal physiological conditions as well as under disease [2]. 
Spliced variants have been shown to play an important role in the progression and detection of 
cancer [84, 85] and include the spliced variants of the genes CD44, WT1,  BRCA1, MDM2, FGFR 
etc. As an example, isoform-specific antibodies for the gene CD44 (specifically the CD44v10) have 
been developed and used in the differentiation of metastatic and nonmetastatic pancreatic cancer 
cells  [84]. Detection of the CD44v10 using immunohistochemical methods could potentially be 
used  clinically,  to  diagnose  gastric  carcinoma  progression  in  patients  [84].  Other  standard 
techniques such as RT-PCR and high-throughput methods such as microarrays can be used to detect 
the splice variants (biomarkers) in a clinical setting [84].
Distinctive genetic markers for MV-induced T cell suppression haven't as yet been defined. The 
production  of  alternatively  spliced  SIP110 by  the  lipid  phosphatase  SHIP145 due  to  PI3K 
interference, might be one of many undiscovered isoforms that can be used as genetic markers for T 
cell suppression. The main aim of this study was to carry out an analysis of cDNA/EST libraries as 
well  as  exon  array  data  to  identify  potential  alternatively  spliced  isoforms  that  are  T  cell 
suppression-specific.  The project  aims  to  address  whether  more  of  these  types  of  alternatively 
spliced  isoforms  exists,  and  could  thus  be  potential  genetic  markers  for  identifying  T  cell 
suppression.
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1.6 Specific objectives
• Analysis  of  publicly  available  microarray  data  and  EST/cDNA  databases  for  the 
alternatively spliced isoforms of the PI3K targets
• Pathway and co-expression analysis of the PI3K targets
• SNP analysis of the alternatively spliced isoforms
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CHAPTER 2
MATERIALS & METHODS
The methods used to identify potential markers of T cell suppression in this project include the 
collection or generation of relevant data, the analysis of the data, merging of data from different 
sources,  and  then  biological  interpretation  through  SNP and  functional  analysis.  A workflow 
diagram outlining the steps taken, is provided in Figure 2.1.
Figure 2.1: Workflow diagram.
Data Collection
In vitro prediction In silico prediction
T cell isolation & RNA extraction Genes involved in T-cell suppression
Generation of alternative splicing data
GeneChip(R) Human Exon 1.0 ST array 
profiling (Affymetrix)
Microarray data in public domain
Gene and isoform selection
Expression under Normal Expression under T-cell suppression 
Gene & isoform Analysis
Variation analysis Functional analysis Co-expression analysis
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2.1 Data collection and generation
In addition to data generated by collaborators within the project, public data was retrieved from a 
number of different sources listed in Table 2.1.
Table 2.1: A summary of the databases used throughout the study.
Database URL
GENECARDS http://www.genecards.org/
ARRAYEXPRESS http://www.ebi.ac.uk/arrayexpress/
NCBI http://www.ncbi.nlm.nih.gov
GEO http://www.ncbi.nlm.nih.gov/geo
GEO2R http://www.ncbi.nlm.nih.gov/geo/geo2r
dbEST http://www.ncbi.nlm.nih.gov/biosample 
BLAST http://blast.ncbi.nlm.nih.gov/Blast.cgi 
DAVID http://david.abcc.ncifcrf.gov
ENSEMBL http://www.ensembl.org/
STRING http://string-db.org/ 
INTERPROSCAN http://www.ebi.ac.uk/Tools/pfa/iprscan/ 
KEGG MAPPER http://www.genome.jp/kegg/mapper.html
2.1.1 Identification of genes predicted to be involved in T cell 
suppression
Genes predicted to be involved in T cell suppression were identified through the use of the gene 
databases from Genecards [69] and NCBI [70]. Querying the databases with the search phrase "T 
cell suppression" resulted in a combined list of 2309 genes.
2.1.2 Retrieval and generation of alternative splicing data through the 
use of microarrays
In silico as well as in vitro experiments were carried out to investigate the PI3K targets and the role 
of alternative splicing in T cell suppression.
2.1.2.1 Generation of alternative splicing data through the use of a GeneChip Exon 
array
A GeneChip Exon array analysis was performed on RNAs isolated from human T cells pre-exposed 
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to wortmannin, or not, prior to a 24 hour phorbolester/ionomycin exposure. Wortmannin is a fungal 
metabolite  known  to  inhibit  PI3K  by  binding  to  the  p110  catalytic  subunit  thus  preventing 
phosphorylation  of  the kinase [83].  The wortmannin was used  in  this  study to  mimic  the  MV 
infection.  The array analysis was performed through a collaboration with our German partners 
from the University of Wuerzburg. The human T cells were enriched on nylon wool columns and 
samples  were  divided  into  2  with  half  the  sample  stimulated  with  40ng/ml  PMA and  0.5µM 
ionomycin  for  24hrs  whilst  the  other  half  was exposed to  50µM of  LY200492 (New England 
Biolabs,  Frankfurt,  Germany)  for  2hrs  and  then  stimulated.   RNA from the  two  samples  was 
extracted using RNeasy Mini Kit (QIAGEN). Quality control was maintained by gel analysis of the 
RNAs. cDNA and cRNA synthesis of 100ng of total RNA of both samples was processed according 
to Affymetrix and then hybridized onto the GeneChip Human Exon 1.0 ST array. The resulting data 
has been deposited in GEO.
2.1.2.2 Extraction of publicly available data
The Gene Expression  Omnibus (GEO) [71]   and ArrayExpress  [72]  databases  were queried  to 
identify  microarray  based  experiments  that  were  done  under  conditions  relating  to  "T  cell 
suppression". A total of 9 experiments were found, 8 in GEO and 1 in ArrayExpress. The list of 
relevant experiments is provided in Table 2.2. 
Table 2.2: Microarray experiments on T cell suppression from GEO and ArrayExpress.
Experiment Description PMID*
GSE6263 Analysis of HCT116 colon cancer cells in which tumor suppressor gene PTEN 
had been deleted by gene targeting
17060456
GSE980 Analysis of dendritic cells for up to 24 hrs after infection with measles virus 16492729
GSE6260 Analysis of CD34+ erythroid progenitors stimulated with erythropoietin (Epo) 
with or without LY294002, a PI3K inhibitor
16965383
GSE9601 Analysis of monocytes treated with an NF-kappaB or PI3K inhibitor and then 
infected  with  the  human  cytomegalovirus  (HCMV).  CMV tends  to  induce 
immunosuppression followed by lasting immunity
18003728
GSE17493 Molecular and functional characterization of alloantigen-specific 
anergic T cell suitable for cell therapy IL-10 anergized
20713457
GSE2729 Expression  profiling  of  peripheral  blood  mononuclear  cells  (PBMCs)  from 
children  with acute  rotavirus  diarrhea  /  rotavirus  activates  B  but  impairs  T 
lymphocytes
17267507
GSE5220 Analysis of CD14+ monocytes from 8 HIV patients at the aviremic state during 
highly active antiretroviral therapy (HAART) and at the viremic state after the 
cessation of HAART. Results provide insight into the impact of HIV infection 
and high-level HIV viremia on the function of monocytes
17005663
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Experiment Description PMID*
E-MTAB-62 Human gene expression atlas of 5372 samples representing 369 different cell  
and tissue types, disease states and cell lines. 
20379172
*PMID - Pubmed ID
2.2 Identification of potential isoforms through the use of microarray 
data
2.2.1 Identification of isoforms from analysis of the GeneChip exon 
array data
Post processing of the exon array, transcripts that were found to be expressed in PI3K inhibited cells 
were  detected  using  an  in-house  developed  algorithm  [64].  The  gene  lists  were  generated  in 
collaboration  with  our  colleagues  at  the  University  of  Wuerzburg.  For  the  workflow  diagram 
outlining the detection of the transcripts, please see Figure 2.2. 
The Expression Console software (Affymetrix) was used for signal estimation, filtering was done 
using the statistical language R and data normalised by quantile-quantile normalisation [73]. Probe 
sets annotated as 'core' were used for the gene and exon level analysis. Signal estimation algorithms 
Figure 2.2: Workflow diagram for the gene- and exon-level analysis.
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PLIER and iterPLIER were used to calculate the expression signal values for the exons and genes 
respectively [53]. The alternatively spliced list was obtained by applying the following thresholds: 
a) A sliding window approach of size 3 was applied to genes with more than 6 exons, b) followed 
by second filtering using a range-cutoff of 0.75 and, c) Splicing Index (SI) of >0.5. 
For differentially expressed genes and exons, a modified t-test was calculated and the following 
thresholds had to be met: a) Genes had a fold change <1.5 and p-value < 0.01, b) exons had to have  
a fold change above 1.35 and c) 90% of all exons had to be differentially expressed.
2.2.2 Identification of isoforms from analysis of public array data
GEO2R  [57]  was  used  to  identify  differentially  expressed  genes  from  the  GEO  experiments 
identified in section 2.1.2.2. The Graphical User Interface (GUI) or the tool uses the GEO to query 
as well as the Limma R packages from the Bioconductor project and doesn't require the user to have 
command line expertise [58]. The output of the results is a table of the top 250 genes ranked by P-
value (the smaller, the more significant) as well as t, B, F statistics and the logFC. The Benjamini & 
Hochberg false discovery rate method was selected to calculate the P-values to adjust between the 
discovery of statistically significant genes and false positives [57]. The t statistic is used to test if 
two samples are different from each other, the B statistic is the log-odds that a gene is differentially 
expressed and a value of 0 means that a gene has a 50-50 chance that it is differentially expressed 
[57]. A fold change (logFC) is a ratio of an experimental sample over the control sample and fold 
change above 2 is deemed significant.
The complete results set was saved into an excel spreadsheet by clicking on "save all results". The 
output table is populated with identifiers such as Accession (probe sets), Title, Source name and the 
fields can be amended by choosing other identifiers using the Columns box [57].
In order to identify differentially expressed genes, GEO2R default parameters were used. For each 
experiment the probe sets, depending on the level of expression, were either assigned as occurring 
under  'Normal'  or  'T  cell  suppression'  conditions.  For  our  research  purposes,  the  level  of 
identification was not sufficient as we needed to identify the isoforms expressed. As the publicly 
identified microarray data are not exon arrays, Ensembl was utilised in identifying the microarray 
probes. 
The mapping of the probes via Ensembl is a 2 step process. Firstly the individual probes are mapped 
to the genome as well as the cDNA sequences and also the alignments capture probes which cover 
the  length  of  the  introns  [59].  A 1bp  mismatch  between  the  probe  and  the  genome sequence 
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assembly is allowed. The second step in the mapping process involves associating the alignments 
identified  in  step  1,  with  the  Ensembl  transcript  predictions  [59].  For  arrays  with  probe  sets, 
Ensembl is set so that 50% of the probes within the set match a transcript. For arrays that do not 
have probe sets, individual probes are matched to a transcript. A probe or probeset is said to match a 
transcript if it overlaps with an exon or the untranslated region (UTR) with at least a 1bp mismatch 
[59].  The  individual  probe  alignments  can  be  accessed  via  the  Ensembl  web  browser 
(http://www.ensembl.org) in the 'Region in detail' view whilst probes that match a transcript can be 
found in the 'Oligo probes'  view in the transcript  page [59].  Other  ways of accessing the data 
involve programmatic access via the ensembl-functgenomics API and via Biomart. We thus queried 
Ensembl using Biomart [59] to extract these details. The Ensembl Genes 67 database was queried, 
with the Homo sapiens genes (GRCh37.p7) as the dataset of choice. To restrict/filter the query, the 
accessions  (probe  sets)  from  the  GEO2R  results  of  the  experiments  (with  the  exception  of 
GEO6260) were used with the appropriate identifier. As the aim of using Biomart was to identify 
what  isoform  the  probe  sets  represented,  under  the  attribute  node  the  features  selected  were 
Associated  Transcript  Name  as  well  as  the  default  Ensembl  Gene  and  Transcript  IDs.  After 
previewing the results, the output was saved.
The  identifiers  used  for  the  GEO6260's  accessions  were  not  available  in  Biomart.  The  NCBI 
BLAST program with the Homo sapiens database [59] was used to align the accessions against the 
RefSeq  DNA database.  The  results  were  then  used  to  query  Biomart  as  done  for  the  other 
microarray experiments.
Post isoform identification, genes that have different isoforms under the normal compared to the  T 
cell suppression conditions were kept for further analysis. To understand the nature of the isoform 
changes  on  a  gene  level,  Ensembl  was  again  queried  for  cDNA/EST evidence  to  support  the 
transcripts,  specifically the non-coding transcripts.  The transcripts identified as  retained introns, 
processed transcript and nonsense-mediated decay are all non-coding and the EST/cDNA evidence 
was used to identify the sources and/or conditions under which these transcripts were found. The 
supporting evidence shows all mRNA and protein entries in public databases (UniProt/SwissProt, 
UniProt/TrEMBL and RefSeq) that were used to make an Ensembl transcript prediction [59]. 
For  genes  that  had  different  protein-coding  transcripts  expressed  under  normal  and  T  cell 
suppression conditions, the functionality of the proteins under the two conditions was examined 
using  InterProScan  [65].  InterProScan  is  a  powerful  tool  that  is  used  to  classify  the  protein 
sequences at different levels such as superfamily, family and subfamily. It compares the sequences 
against  the InterPro member databases  which include PROSITE, PRINTS, Pfam, SMART etc., 
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resulting in the characterisation of the protein's domains and/or functional sites [65]. The different 
InterPro member databases have different strengths, for example, PROSITE is used to find short 
motifs whilst PRINTS is good for sub-family membership and by combining multiple databases, 
InterProScan ensures that reliable results are obtained for a given protein sequence [65]. The amino 
acid  sequences  of  the  isoforms  that  are  protein-coding  were  retrieved  in  FASTA format  from 
Ensembl, and run through InterProScan [65].
2.3 Variation analysis
The  Ensembl  Variation  67  database  was  queried,  with  Homo  sapiens Variation  (dbSNP 
135;ENSEMBL) as the dataset of choice. SNPs were selected based on the following criteria: 1. 
should have phenotype data,  2.  the SNP should be located in the splice site,  i.e.  can influence 
alternative  splicing  and  thus  the  function  of  the  gene  or  3.  the  SNP be  located  in  a  splicing 
regulatory  element  (SRE)  for  example  an ESE. Genes  that  satisfied  the  criteria  were analysed 
further. 
2.4 Functional analysis
2.4.1 Enrichment and pathway analysis
Functional analysis was performed on gene lists using the Database for Annotation, Visualisation 
and Integrated Discovery (DAVID) web-based tool [60]. The default parameter of count 2 was used 
together with a lowered Ease score (p-value) of 0.01 from 0.1 (the lower the Ease score the more 
enriched the terms are). KEGG Mapper [74] was also used as a database of choice and used to map 
the genes onto pathways. This tool takes a gene list and searches for KEGG pathways the genes are  
involved in, providing the KEGG maps with the relevant genes in highlighted the colour chosen by 
the user. If no colour is defined, the default is pink.
2.4.2 Interaction analysis with STRING (Search Tool for the Retrieval of 
Interacting Genes/Proteins)
STRING [62], a database of known and predicted protein interactions, was also used to find, if any, 
interactions  between  PIK3CA and  the  other  genes  resulting  from the  analysis.  PIK3CA is  the 
catalytic subunit of the phosphatidyl-inositol-3-kinase (PI3K). The PI3K/AKT signaling pathway is 
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targeted by the measles virus (MV) in T cells. The pathway is important in a number of cellular 
processes such as cell growth, proliferation and survival and interference of the signaling by MV 
results in the arrest of the cell cycle in T lymphocytes leading to T cell suppression. The direct and 
indirect interactions obtained from STRING, are derived from seven sources: neighbourhood, gene 
fusion, cooccurence, coexpression, experiments, databases and textmining [63].
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CHAPTER 3
RESULTS
The aim of the project was to identify markers of T cell suppression. This was achieved by using 
publicly  available  as  well  as  internally  generated  microarray  data  in  order  to  predict  the 
alternatively  spliced  isoforms   that  could  potentially  be  used  as  genetic  markers  for  T  cell 
suppression.
3.1 Identification of genes predicted to be involved in T cell suppression
In order to identify genes involved in T cell suppression, we searched Genecards [69] and NCBI 
[70]. This resulted in a list of 2309 genes, which is provided in the Appendix A.
3.2 Identification of potential isoforms through the use of microarray 
data
3.2.1 Identification of alternatively spliced genes from the GeneChip 
exon array
A GeneChip exon array experiment was performed by our collaborators from the University of 
Wuerzburg. Preprocessing and analysis of the exon array was done as described in the methods 
section to detect transcripts specifically expressed in PI3K inhibited cells. These were assigned to 
categories defining differentially regulated (DR) (654 candidates) and alternatively spliced (AS) 
species  (1985  candidates)  [63].  To  be  considered  alternatively  spliced,  candidate  genes  were 
obtained by applying the following thresholds: a) A sliding window approach of size 3 was applied 
to the genes with more than 6 exons, b) followed by second filtering using a range-cutoff of 0.75 
and, c) Splicing Index (SI) of >0.5. For the differentially expressed genes and exons, a modified t-
test was calculated and genes had to have a fold change <1.5 and p-value < 0.01 whilst exons had to 
have  a  fold  change  above  1.35  and  that  90% of  all  exons  had  to  be  differentially  expressed. 
Validation of a selection of transcripts, based on signal intensities and splice indices, was carried out 
through the use of RT-PCR. Functional annotation and analysis of representation of these genes in 
molecular networks and pathways was carried out. 
Applying filters described in the methods section, 1985 genes were assigned as being alternatively 
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spliced whilst 654 genes were differentially regulated. Nine and seven candidate genes from the 
differentially regulated and alternatively spliced list respectively, were chosen for validation using 
RT-PCR. It was found that gene assignment to both categories seemed valid. Please see work done 
by Riedel et. al for more detail [63].
DAVID [60] was used for functional analysis. Only pathways that showed a p-value < 0.01 and at 
least 5 genes were considered to be significantly enriched. The analysis revealed that alternatively 
spliced genes were involved in extra cellular matrix (ECM)-receptor interaction and focal adhesion, 
purine metabolism, and natural killer cell mediated cytotoxicity. The differentially regulated list was 
associated with cytokine-receptor interaction, the Jak-STAT and p53 pathways, as well as DNA 
replication. Cell cycle regulation was enriched in both the alternatively spliced and the differentially 
regulated lists.
3.2.2 Intersection of publicly identified genes and GeneChip Exon array 
genes
We then determined whether there was an overlap between the genes from the exon array and those 
retrieved from gene databases using T cell suppression and related search terms. An overlap of the 
differentially regulated (654) as well as the alternatively spliced (1985) genes was found with the 
genes identified in section 3.1. Figure 3.1 illustrates the intersection between the 3 gene lists.
The genes that intersected were kept for further analysis and are listed in the next page in Table 3.1.
Figure 3.1: An intersection of the identified genes. AS: alternatively spliced genes from the  
GeneChip exon array; PI: publicly identified genes and DR: differentially regulated genes  
from the GeneChip exon array. Genes that intersected were kept for further analysis.
DR
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230987 19
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Table 3.1:  An intersection of publicly identified genes and genes from the GeneChip exon array.
Gene Description Assignment*
AGAP2 ArfGAP with GTPase domain, ankyrin repeat and PH domain 2 AS
ALCAM activated leukocyte cell adhesion molecule DR
AMPD3 adenosine monophosphate deaminase 3 AS
AR androgen receptor AS
ATM ataxia telangiectasia mutated DR
BACE1 beta-site APP-cleaving enzyme 1 AS
BIN1 bridging integrator 1 AS
BMP4 bone morphogenetic protein 4 AS
BRCA1 breast cancer 1, early onset AS
CALD1 caldesmon 1 AS
CCDC50 coiled-coil domain containing 50 AS
CD244 CD244 molecule, natural killer cell receptor 2B4 AS
CD44 CD44 molecule (Indian blood group) AS
CD79B CD79b molecule, immunoglobulin-associated beta AS
CDC25A cell division cycle 25 homolog A (S. pombe) AS
CDH11 cadherin 11, type 2, OB-cadherin (osteoblast) AS
CDKN1A cyclin-dependent kinase inhibitor 1A (p21, Cip1) DR
CFB complement factor B AS
CHAF1A chromatin assembly factor 1, subunit A (p150) AS
CHN1 chimerin (chimaerin) 1 AS
CTLA4 cytotoxic T-lymphocyte-associated protein 4 DR
DDX58 DEAD (Asp-Glu-Ala-Asp) box polypeptide 58 AS
DFFB DNA  fragmentation  factor,  40kDa,  beta  polypeptide  (caspase-
activated DNase) 
AS
DUT deoxyuridine triphosphatase AS
ELAC2 elaC homolog 2 (E. coli) DR
EPB49 erythrocyte membrane protein band 4.9 (dematin) AS
ERCC1 excision  repair  cross-complementing  rodent  repair  deficiency, 
complementation  group  1  (includes  overlapping  antisense 
sequence) 
AS
ETV7 ets variant 7 AS
EXO1 exonuclease 1 AS
FANCD2 Fanconi anemia, complementation group D2 AS
FCGR2B Fc fragment of IgG, low affinity IIb, receptor (CD32) AS
FCGR2C Fc  fragment  of  IgG,  low  affinity  IIc,  receptor  for  (CD32) 
(gene/pseudogene) 
AS
FLT3LG fms-related tyrosine kinase 3 ligand AS
GAD1 glutamate decarboxylase 1 (brain, 67kDa) AS
GCK glucokinase (hexokinase 4) AS
GRIA3 glutamate receptor, ionotropic, AMPA 3 AS
HDAC5 histone deacetylase 5 AS
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
43
HDAC9 histone deacetylase 9 AS
HPR haptoglobin-related protein AS
ICOS inducible T cell co-stimulator DR
IKZF1 IKAROS family zinc finger 1 (Ikaros) DR
IL12RB1 interleukin 12 receptor, beta 1 AS
IMPDH1 IMP (inosine 5'-monophosphate) dehydrogenase 1 AS
INPPL1 inositol polyphosphate phosphatase-like 1 AS
IRAK1 interleukin-1 receptor-associated kinase 1 AS
IRF7 interferon regulatory factor 7 DR
ITGAM integrin, alpha M (complement component 3 receptor 3 subunit) AS
ITGAV integrin, alpha V (vitronectin receptor, alpha polypeptide, antigen 
CD51) 
DR
KCNQ1 potassium voltage-gated channel, KQT-like subfamily, member 1 AS
KCNQ5 potassium voltage-gated channel, KQT-like subfamily, member 5 DR
KHK ketohexokinase (fructokinase) AS
KIAA0913 KIAA0913 DR
KIT v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog AS
KLRC3 killer cell lectin-like receptor subfamily C, member 3 DR
LAMA3 laminin, alpha 3 AS
LCK lymphocyte-specific protein tyrosine kinase AS
MAP3K12 mitogen-activated protein kinase kinase kinase 12 AS
MCM7 minichromosome maintenance complex component 7 DR
MEN1 multiple endocrine neoplasia I AS
MEST mesoderm specific transcript homolog (mouse) AS
MKI67 antigen identified by monoclonal antibody Ki-67 AS
MUC1 mucin 1, cell surface associated AS
MXI1 MAX interactor 1 AS
MYB v-myb myeloblastosis viral oncogene homolog (avian) AS
MYH10 myosin, heavy chain 10, non-muscle AS
NAB2 NGFI-A binding protein 2 (EGR1 binding protein 2) AS
NRP1 neuropilin 1 AS
OGDH oxoglutarate (alpha-ketoglutarate) dehydrogenase (lipoamide) DR
OPN4 opsin 4 DR
P4HTM prolyl 4-hydroxylase, transmembrane (endoplasmic reticulum) AS
PCGF6 polycomb group ring finger 6 AS
PDE2A phosphodiesterase 2A, cGMP-stimulated AS
PLAT plasminogen activator, tissue AS
PNPLA8 patatin-like phospholipase domain containing 8 DR
PPARGC1B peroxisome proliferator-activated  receptor  gamma,  coactivator  1 
beta 
AS
PRDM10 PR domain containing 10 AS
PRMT5 protein arginine methyltransferase 5 DR
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PTK7 PTK7 protein tyrosine kinase 7 AS
PVRL2 poliovirus receptor-related 2 (herpesvirus entry mediator B) AS
RAD1 RAD1 homolog (S. pombe) AS
RARA retinoic acid receptor, alpha AS
RARG retinoic acid receptor, gamma AS
RASGRF1 Ras protein-specific guanine nucleotide-releasing factor 1 AS
RASSF5 Ras association (RalGDS/AF-6) domain family member 5 AS
RBBP6 retinoblastoma binding protein 6 AS
RBL1 retinoblastoma-like 1 (p107) AS
RUNX3 runt-related transcription factor 3 AS
SEMA3B sema domain, immunoglobulin domain (Ig),  short basic domain, 
secreted, (semaphorin) 3B 
AS
SGOL1 shugoshin-like 1 (S. pombe) DR
SIRT2 sirtuin 2 AS
SLC25A14 solute carrier family 25 (mitochondrial carrier, brain), member 14 AS
SLCO4A1 solute carrier organic anion transporter family, member 4A1 AS
SMAD6 SMAD family member 6 AS
SMG1 smg-1 homolog, phosphatidylinositol  3-kinase-related kinase (C. 
elegans) 
AS
SPHK1 sphingosine kinase 1 AS
SPP1 secreted phosphoprotein 1 AS
STK36 serine/threonine kinase 36 AS
SYK spleen tyrosine kinase AS
TLR4 toll-like receptor 4 AS
TNC tenascin C AS
TRPV4 transient receptor potential cation channel, subfamily V, member 4 AS
UBD ubiquitin D AS
USF2 upstream transcription factor 2, c-fos interacting AS
VCL vinculin DR
VWCE von Willebrand factor C and EGF domains AS
WWC1 WW and C2 domain containing 1 AS
*Assignment: AS - Alternatively Spliced; DR - Differentially Regulated
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3.2.3  Identification of isoforms from the public microarray data
Publicly available microarray data were used to identify potential isoforms that might be formed 
during normal and T cell suppression conditions as well as to provide further support for the genes 
that overlapped with those identified through the use of the GeneChip Exon array. GEO2R [57] was 
used  to  identify  the  alternatively  spliced  isoforms  from  the  different  microarray  data.  As  the 
publicly  identified  microarray  data  are  not  exon  arrays,  Ensembl  was  used  to  identify  the 
microarray probes. Ensembl starts by mapping the individual probes to the genome as well as the 
cDNA sequences  with room for  a  1bp mismatch between the  probe and the  genome sequence 
assembly.  The  second  step  involves  associating  the  alignments  identified  in  step  1,  with  the 
Ensembl transcript predictions [59]. A probe or probeset is said to match a transcript if it overlaps 
with an exon or the untranslated region (UTR) with at  least  a 1bp mismatch.  We thus queried 
Ensembl using Biomart [59] to extract the required details.
Two sets of gene lists were created as a result of the Biomart search, namely a list of genes that had 
different isoforms expressed under the different conditions whilst another list was of genes that had 
different isoforms all expressed under a single condition. Genes that exhibited different isoforms 
under different conditions were kept for further analysis. The following genes that overlapped with 
the GeneChip exon array, had different isoforms formed under normal versus T cell suppression 
conditions: ATM, CALD1, LCK, VCL, MXI1, NRP1 and PRMT5. See Table 3.2 for summary of the 
identified isoforms. ATM, VCL and PRMT5 were found to be differentially regulated on the whole 
transcript level using the GeneChip exon array, while CALD1, LCK, MXI1 and  NRP1 were shown 
to be alternatively spliced.
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3.3 Gene expression levels of isoforms identified from microarray data
3.3.1 GeneChip exon array: probe set intensity plots
Log ratio of the probe set intensities, which show the abundance of a transcript, for the 
genes identified in section 3.2.3 were plotted. Figure 3.2 illustrates the gene views of the 
probe set intensity plots for the genes  LCK and  PRMT5 as well as the different transcript 
profiles, of the genes, below the graphs. The plots are for the stimulated samples (red line) 
and both stimulated and inhibited samples (blue line).  LCK was found to be alternatively 
spliced as there were regions in the gene where the probe set expressions were found to be 
different between the stimulated samples and the inhibited/stimulated samples whilst other 
regions the expression was the same between the different samples as the SI<0.5.  PRMT5 
on the other hand was differentially regulated as the different samples showed different 
expression levels throughout the gene.
Please refer to Appendix B to view plots for ATM, VCL, CALD1, MXI1 and NRP1. 
Table 3.2: Genes that have different isoforms under Normal vs. T cell suppression conditions.
Ensembl Gene ID Condition Experiment
ENSG00000149311 ENST00000527805 ATM-001 Normal YES GSE980
ENSG00000149311 ENST00000530958 ATM-002 T-cell suppression YES GSE980
ENSG00000149311 ENST00000526567 ATM-004 T-cell suppression YES GSE980
ENSG00000149311 ENST00000532931 ATM-016 Normal YES GSE980
ENSG00000122786 ENST00000430085 CALD1-004 T-cell suppression YES GSE9601, GSE6263, GSE5220
ENSG00000122786 ENST00000482470 CALD1-008 Normal YES GSE6263, GSE5220
ENSG00000122786 ENST00000543443 CALD1-204 T-cell suppression YES GSE5220, GSE6263
ENSG00000182866 ENST00000495610 LCK-006 Normal YES GSE6263 
ENSG00000182866 ENST00000373557 LCK-010 T-cell suppression YES GSE980
ENSG00000182866 ENST00000477031 LCK-011 T-cell suppression YES GSE980
ENSG00000182866 ENST00000398345 LCK-202 Normal YES GSE9601 
ENSG00000119950 ENST00000369613 MXI1-001 T-cell suppression YES GSE9601 
ENSG00000119950 ENST00000369614 MXI1-002 T-cell suppression YES GSE9601 
ENSG00000119950 ENST00000460667 MXI1-003 T-cell suppression YES GSE9601 
ENSG00000119950 ENST00000485566 MXI1-007 Normal YES GSE980
ENSG00000119950 ENST00000393134 MXI1-009 T-cell suppression YES GSE9601 
ENSG00000119950 ENST00000369612 MXI1-011 T-cell suppression YES GSE9601 
ENSG00000119950 ENST00000484030 MXI1-012 T-cell suppression YES GSE9601 
ENSG00000119950 ENST00000369619 MXI1-201 T-cell suppression YES GSE9601 
ENSG00000035403 ENST00000372755 VCL-001 Normal YES E-MTAB62, GSE980
ENSG00000035403 ENST00000415462 VCL-202 T-cell suppression YES E-MTAB62
ENSG00000035403 ENST00000537043 VCL-204 Normal YES E-MTAB62, GSE980
ENSG00000099250 ENST00000265371 NRP1-001 T-cell suppression YES GSE6263, GSE26050
ENSG00000099250 ENST00000374823 NRP1-005 T-cell suppression YES GSE6263, GSE26050
ENSG00000099250 ENST00000374814 NRP1-201 Normal YES GSE6263, GSE26050
ENSG00000100462 ENST00000557443 PRMT5-006 Normal YES GSE26050
ENSG00000100462 ENST00000553550 PRMT5-014 T-cell suppression YES GSE17493
ENSG00000100462 ENST00000553502 PRMT5-017 T-cell suppression YES GSE17493
ENSG00000100462 ENST00000556043 PRMT5-018 T-cell suppression YES GSE17493
ENSG00000100462 ENST00000555530 PRMT5-020 T-cell suppression YES GSE17493
ENSG00000100462 ENST00000553787 PRMT5-025 T-cell suppression YES GSE17493
Ensembl 
Transcript ID
Associated 
Transcript Name
RefSeq / EST 
evidence
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Figure 3.2: Probe set intensity plots for the alternatively spliced gene LCK and differentially  
regulated gene PRMT5. Accession numbers of the alternatively spliced forms are provided  
below each panel.  A: LCK is alternatively spliced due to regions in the gene where the probe  
set  expressions  are  different  between  the  stimulated  and  the  inhibited/stimulated  samples  
whilst other regions have the same expression between the different samples.  B: PRMT5 is  
differentially regulated as the different samples showed different expression levels throughout.
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3.3.2 Publicly identified microarray data
3.3.2.1 Different transcripts, different conditions
The  log  fold  changes  and  p-values  (were  calculated  using  the  Benjamini  &  Hochberg  false 
discovery rate method) for the different experiments retrieved from GEO and ArrayExpress were 
calculated using GEO2R, see section 2.2.2. For each experiment, using GEO2R, samples within an 
experiment were assigned to two groups, i.e. a control and a test group and the log fold change was 
calculated between the two experimental conditions [57]. See Table 3.3 for the condition under 
which the log fold changes were calculated. The p-value was log transformed and the higher the 
value, the more significant the probe's expression, whilst a fold change of 2 or above is desired. Log 
transformed p-values  for  the  probes  belonging to  the same gene,  were  plotted  against  the fold 
change expressions for the seven genes that overlapped with the GeneChip exon array gene lists 
(Figure 3.3). The graphs were generated using  OpenOffice.org Calc [64]. 
Table 3.3: Conditions under which the log fold changes were calculated
Experiment Control Test
GSE6263 Human colon cancer cells with intact PTEN Human colon cancer cells with deleted PTEN
GSE980 Monocyte-derived dendritic cells Measles virus-infected dendritic cells
GSE6260 Erythroid progenitors cultured in medium Erythroid progenitors stimulated with EPO and LY
GSE9601 HCMV-infected monocytes HCMV-infected monocytes pretreated with LY
GSE17493 CD3-depleted cells CD3-depleted cells stimulated with IL-10
GSE2729 Peripheral blood mononuclear cells (PBMC) Rotavirus-infected PBMC
GSE5220 HIV-infected monocytes on HAART HIV-infected monocytes off HAART
E-MTAB-62 Healthy PBMC PBMC with: trauma; anergy; HIV 
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Figure 3.3: Expression levels of the gene's probes from public array data for the seven genes of  
interest. The P-values for the probes of the different genes are graphed (red line), along with  
the fold change expression levels (coloured bars, see legend).
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ATM
For the gene ATM, probe 1863_s_at, representing isoforms ATM-001 and ATM-016 was found to be 
expressed under normal conditions in the experiment GSE980  whilst ATM-002 and ATM-004 were 
expressed under T cell suppression conditions and represented by the probe 1862_at in the same 
experiment. The probe 1863_s_at was expressed under normal conditions at a significant p-value of 
0.0014 whilst  the probe 1862_at had an insignificant p-value of 0.313. Probes 208442_s_at (p-
value=0.3614), 212672_at (p-value=0.4407) and 210858_x_at (p-value=0.7823) were all expressed 
under T cell suppression conditions in the experiment GSE6263.
LCK
Transcripts  LCK-006,  represented  by  probe  204890_s_at  (p  value  =  0.111  and  0.0000037, 
respectively) in experiments GSE26050 and GSE6263, LCK-010 and LCK-011, both represented 
by probe 1266_s_at (p-value =0.00948) in the experiment GSE980, were all expressed under T-cell 
suppression conditions. LCK-202 represented by probes 2059_s_at (p-value=0.0379) and 33238_at 
(p-value= 0.0782) had significant expression under normal conditions in the experiment GSE9601.
CALD1
CALD1-008 represented by probe 205525_at (p-value of 0.2357 and 0.5832) was expressed under 
normal  conditions  in  the  experiments  GSE6263 and GSE5220 whilst  under  T cell  suppression 
conditions CALD1-004 represented by probe 201617_x_at (p-value of 0.319 and 0.3575) and probe 
201616_s_at (p-value of 0.389) was expressed in both the experiments GSE6263 and GSE5220. 
CALD1-204 (probe 201616_s_at with p-value of 0.389) was expressed in the experiment GSE5220 
under T cell suppression conditions.
MXI1
Seven MXI1 transcripts, represented by probe 748_s_at with p-value of 0.08, were expressed under 
T cell  suppression  conditions,  namely  MXI1-009,  MXI1-011,  MXI1-201,  MXI1-001,  MXI1-002, 
MXI1-003  and MXI1-012.  MXI1-007  represented  by  probe  39072_at  (p-value  of  0.006)  in 
experiment GSE980, probe  654_at (p-value of 0.009) in experiment GSE980 and probe 202364_at 
(p-value of 0.00000013) in experiment GSE26050 was the only isoform found to be expressed 
under normal conditions.
VCL
VCL-001 and  VCL-204,  represented by the probes  200931_s_at  (p-value of  0.1 e-9) and probe 
36601_at  (p-value  of  0.000828) were  expressed  under  normal  conditions  in  the  experiments 
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GSE980 and E-MTAB-62.  VCL-202 represented  by probe 200930_s_at  (p-value of  0.016)  was 
expressed under T cell suppression conditions in the experiment E-MTAB-62.
PRMT5
Probe 8195 was found expressed in the experiment GSE6260 under normal conditions with a p-
value  of  0.9242.  Probes  1564520_s_at  (p-value of  0.0044),  217786_at  (p-value  of  0.0151) and 
1564521_x_at (p-value of 0.0313) were all expressed in the experiment GSE26050 under T cell 
suppression  conditions.  Isoform  PRMT5-006  is  represented  by  probe  8195  and  the  probes 
expressed  under  T  cell  suppression  conditions  represent  isoforms  PRMT5-014,  PRMT5-017, 
PRMT5-018, PRMT5-020 and PRMT5-025.
NRP1
The probe 1561365_at (p-value of 0.689), representing isoform NRP1-201, was found expressed 
under normal conditions in the experiment GSE26050. Probes A_24_P59327(p-value=0.2583) and 
210615_at (p-value=0.1270 and 0.0189)  both code for NRP1-005 and were found expressed under 
T cell suppression conditions in the experiments GSE17493, GSE26050 and GSE6263. Isoform 
NRP1-001, represented by probe A_24_P135322 (p-value=0.3981), was found expressed under T 
cell suppression conditions as well in the experiment GSE17493.
3.3.2.2 Different transcripts, same condition
The gene CD44, which is known to produce spliced isoforms, appeared under the list of genes that 
have isoforms produced under only one condition, either normal or T cell suppression but not both. 
The list, not shown, also included the gene  INPPL1 which is part of the SHIP family of genes. 
Genes such as BRCA1,  FGF1 and PSEN1 were also on the list. This is interesting as these genes' 
alternative splicing has been well studied [49].
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3.4 Gene summaries, EST/cDNA evidence and protein functionality
The following section highlights the gene summaries, from Ensembl [59], of the genes identified in 
section 3.2.3. The graphs of the gene summaries show the distribution of the exons of the different 
isoforms  along  the  chromosomes.  EST/cDNA supporting  evidence  for  the  transcripts  are  also 
included for the transcripts identified as non-coding, i.e. retained introns, processed transcripts and 
nonsense-mediated decay.  For genes that had different protein-coding transcripts expressed under 
both normal compared to T cell suppression conditions, the functionality of the proteins under the 
two conditions was examined using InterProscan [65] by looking at  the protein's domains. The 
different isoforms identified in section 3.2.3, are shown with arrows in the graphs. The green arrow 
identifies  isoforms  expressed  under  normal  conditions  and  the  purple  arrow  is  for  isoforms 
expressed under T cell suppression conditions.
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3.4.1 ATM 
3.4.1.1 ATM gene summary 
Four transcripts were identified from probes that were found to be expressed under the different 
conditions. ATM-001 and ATM-016 were expressed under normal conditions and are protein-coding 
with ATM-001 being the longer isoform. The transcripts found under T cell suppression conditions 
were ATM-002 and  ATM-004, both retained introns and are predicted to have no protein product. 
Supporting evidence for the transcripts  ATM-002 and ATM-004 is provided in Figure 3.5.
  
Figure 3.4: ATM gene summary modified from Ensembl. The longer ATM-001 and the short ATM-
016  were  found  expressed  under  normal  conditions.  ATM-002  and  ATM-004,  both  retained  
introns with no protein products, were found expressed under T cell suppression conditions.
Normal T-cell suppression
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3.4.1.2 ATM supporting evidence 
Not much supporting evidence exists for these non-coding transcripts. ATM-004 has both EST and 
cDNA supporting all exons whilst for the transcript ATM-002 only cDNA evidence supports all the 
exons.  For  ATM-002, AB209133.1  was  found  expressed  in  brain  tissue,  BQ723233.1  and 
BC061584.1 were found expressed in the sympathetic trunk (nerve fibres that run between the base 
of the skull and the tailbone) of a 16 year old male. ATM-004 had the same supporting evidence as 
ATM-002 but supporting different exons.
ATM-002
ATM-004
Figure 3.5: Ensembl EST/cDNA supporting evidence for the ATM-002 and ATM-004 transcripts.
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3.4.2 CALD1 
3.4.2.1 CALD1 gene summary
CALD1-204 and CALD1-004 are expressed under T cell suppression whilst CALD1-008 was found 
expressed under normal conditions. CALD1-004 and CALD1-008 are both non-coding and CALD1-
204 is protein-coding. The difference between the non-coding transcripts, CALD1-004 and CALD1-
008, is not only the number of exons but CALD1-008 has an untranslated region (UTR).
  
Figure 3.6:  CALD1 gene summary modified from Ensembl. The protein-coding CALD1-204 was  
found expressed under T cell suppression conditions together with the non-coding CALD1-004.  
CALD1-008, also non-coding, was expressed under normal conditions.
Normal T-cell suppression
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3.4.2.2 CALD1 supporting evidence 
For both CALD1-008 and CALD1-004 while there is no transcript evidence, there is plenty of exon 
supporting evidence that interestingly includes evidence at  the protein level given the supposed 
non-coding ability of the transcripts. According to this evidence, CALD1-008 is mainly expressed in 
non-muscle tissues or cells such as amygdala and is also found in smooth muscles. The cDNA 
AK304729.1  supports  all  of  the  CALD1-004 exons  and  was  found  expressed  in  the  library 
LIBEST_018544 UTERU3 in the  uterus tissue.
CALD1-008
CALD1-004
Figure 3.7: Ensembl EST/cDNA supporting evidence for the CALD1 transcripts. CALD1-008 was  
found expressed in both non-muscle and smooth muscle tissues. CALD1-004 was found in the  
uterus.
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3.4.3 MXI1 
3.4.3.1 MXI1 gene summary 
The MXI1-007 which is a processed transcript (non-coding transcript without an ORF), was found 
to be expressed under normal conditions. Transcripts expressed under T cell suppression conditions 
were  a  mixture  of  protein-coding  and  non-coding.  Supporting  evidence  for  the  non-coding 
transcripts is shown in section 3.4.3.2.
  
Figure 3.8: MXI1 gene summary modified from Ensembl. MXI1-007, a non-coding transcript  
without an ORF, was found expressed under normal conditions whilst a mixture of protein-
coding and non-coding transcripts was found expressed under T cell suppression conditions.
Normal T-cell suppression
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3.4.3.2 MXI1 supporting evidence 
Just like the  ATM non-coding transcripts,  there seem to be very little  evidence for these  MXI1 
transcripts. The EST BQ425277.1 evidence was found in skin tissue and the cDNA BC016678.1 
was  found  expressed  in  skin  tissue  with  melanotic  melanoma  generated  from  the  library 
NIH_MGC_72.
MXI1-003
MXI1-007
MXI1-012
Figure  3.9: Ensembl  EST/cDNA supporting  evidence  for  the  MXI1  transcripts.  The  MXI1  
transcripts were found expressed on skin tissue.
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3.4.4 LCK 
3.4.4.1 LCK gene summary 
All the transcripts identified for LCK are protein-coding. Three of the transcripts, LCK-010, LCK-
011 and LCK-006 were found to be expressed under T cell suppression conditions whilst LCK-202 
was found under normal conditions. As for both conditions all the transcripts are protein-coding, 
domains of the proteins were examined using InterProScan [65] to assess how the proteins differ 
functionally between the normal and suppressed conditions.  Please see section 3.4.4.2 for more 
details.
Figure 3.10: LCK gene summary modified from Ensembl. All the identified transcripts are protein-
coding. LCK-010, LCK-011 and LCK-006 were expressed under T cell  suppression conditions  
whilst LCK-202 was expressed under normal conditions. InterProScan was used to examine the  
domains of the proteins in section 3.4.4.2.
Normal T-cell suppression
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3.4.4.2 LCK protein functional analysis - InterProScan
Running the protein sequence of  LCK-202 through InterProScan results in 5 domain matches as 
well as 1 active site match (Figure 3.11). The domains belong to the protein kinase family and are: 
• Protein kinase, catalytic domain (IPR000719)
◦ This domain is found in serine/threonine-protein kinases, tyrosine-protein kinases and 
dual  specificity  protein  kinases.  Protein  kinases  play  an  important  role  in  cellular 
processes  such  as  proliferation,  differentiation  and  apoptosis  [65].  The  domain  has 
conserved regions such as the N-terminal of the domain has glycine rich residues that are 
involved in ATP binding whilst the middle of the domain has an aspartic acid residue 
which is crucial in the functionality of the kinase [65].
◦ The 3-D fold of this domain is similar to the PI3K catalytic domain [65].
• Serine-threonine/tyrosine-protein kinase catalytic domain (IPR001245)
• Tyrosine-protein kinase, active site (IPR008266)
◦ The kinase can transfer a phosphate group from ATP to a tyrosine residue in a protein 
and are divided into two groups, the receptor  and cytoplasmic/non-receptor tyrosine 
kinases.
• Protein kinase-like domain (IPR011009) and 
• Tyrosine-protein kinase, catalytic domain (IPR020635). 
Figure 3.11: LCK protein characterisation using InterProScan. The InterProScan result showed 
that LCK-202 is the most complex of the transcripts whilst LCK-011 has low complexity.
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The InterProScan result for the protein sequence of LCK-006 matched 5 domains, namely:
• Protein kinase, catalytic domain (IPR000719)
• SH2 domain (IPR000980)
◦ The SH2 domain is found within the Src oncoprotein as well as other signal-transducing 
proteins.  The  domain  functions  to  recognise  the  phophorylated  tyrosine  residues  on 
proteins and thus aids other proteins to bind the tyrosine phosphorylated sites.
• Serine-threonine/tyrosine-protein kinase catalytic domain (IPR001245)
• Src homology-3 domain (IPR001452)
◦ The 55aa  proteins  are  found in  membrane-associated  proteins  such as  proteins  with 
enzymatic activity, in adaptor proteins without catalytic sequences and in cytoskeletal 
proteins.
• Protein kinase-like domain (IPR011009)
LCK-010 InterProScan results returned only two hits, namely the SH2 domain (IPR000980) and the 
Src homology-3 domain (IPR001452). LCK-011 protein search resulted in no matches.
The InterProScan result show that LCK-202 is the most complex of the transcripts whilst LCK-011 
has low complexity.  Both  LCK-202 and  LCK-006 were expressed under normal conditions and 
seem to have similar domains except for the lack of the SH2 domain and the Src homology-3 
domain in LCK-202. LCK-010 lacks the protein kinase domains whilst LCK-011 seem to be a very 
simple protein; both transcripts were found expressed under T cell suppression conditions. In the 
case of LCK, it seems that the loss of certain domains (e.g. the protein kinase-like domain) is what 
may contribute to the immunosuppression of the T cells.
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3.4.5 VCL 
3.4.5.1 VCL gene summary 
Transcripts VCL-001 and VCL-204 were found to be expressed under normal conditions with VCL-
202 expressed under T cell  suppression conditions.  The transcripts  are very similar  except that 
VCL-202 is truncated. As all the transcripts are protein-coding, protein functionality was examined 
using InterProScan. Please see section 3.4.5.2, Figure 3.13.
Figure 3.12: VCL gene summary modified from Ensembl. All the identified VCL transcripts are  
protein-coding.  VCL-001  and  VCL-204  are  expressed  under  normal  conditions  whilst  the  
truncated  transcript,  VCL-202,  was  found  expressed  under  T cell  suppression  conditions.  
InterProScan was used to examine the domains of the proteins in section 3.4.5.2.
Normal
T-cell suppression
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3.4.5.2 VCL protein functional analysis - InterProScan
Three InterProScan entries matched the protein sequence of VCL-001 and VCL-204, namely:
• Vinculin, conserved site (IPR000633)
• Vinculin/alpha-catenin (IPR006077)
◦ Alpha-catenins are related to vinculin and associate with the cytoplasmic domain of a 
variety of cadherins resulting in a complex that is linked to the actin filament network, 
and is important in the cadherins cell-adhesion properties. There are three types: alpha, 
VCL-001 and VCL-204
VCL-202
Figure 3.13: VCL protein characterisation using InterProScan. VCL-001 and VCL-204 both have 
all of the 7 motifs present on the transcripts whilst  VCL-202  has lost some of the conserved  
motifs and only has the proline-rich motifs 1 and 2 present on the transcript.
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beta, and gamma. Alpha-catenins are related to vinculin but lack the repeated domain as 
well as the proline-rich segment. 
• Vinculin (IPR017997)
◦ The protein has 7 motifs that were drawn from conserved regions of the C-terminal; 
motifs 1 and 2 are in the proline-rich region and the rest of the motifs 3-7 are in the C-
terminal domain [65].
VCL-001 and VCL-204 both expressed under normal conditions, and have all of the 7 motifs present 
on the transcripts. VCL-202, which is found under T cell suppression conditions, has lost some of 
the conserved motifs and only has the proline-rich motifs 1 and 2 present on the transcript. Motif 1 
has the following sequence (DELAPPKPPLP) and is located at position 763-773 on the VCL-202 
protein sequence whilst motif 2 is located at position 778-791 on the transcript and its amino acid 
sequence  is  (PPPRPPPPEEKDEE).  The  poly-proline  regions  are  known  to  form  a  helical 
conformation  that  aids  in  intermolecular  interactions  such  as  signal  transduction,  antigen 
recognition, cell-cell communication and cytoskeletal organization [75].
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3.4.6 NRP1
3.4.6.1 NRP1 gene summary
Transcripts  NRP1-001 and  NRP1-005 were expressed under T cell suppression conditions whilst 
NRP1-201 was  expressed under  normal  conditions.  All  transcripts  are  protein-coding and were 
further analysed using InterProScan in section 3.4.6.2.
Figure 3.14: NRP1 gene summary modified from Ensembl. All the identified transcripts are protein-
coding. NRP1-001 and NRP1-005 was expressed under T cell suppression conditions whilst NRP1-
201 was expressed under normal conditions. InterProScan was used to examine the domains of the  
proteins in section 3.4.6.2.
Normal T-cell suppression
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3.4.6.2 NRP1 protein functional analysis - InterProScan
Seven hits matched the NRP1-001 protein sequence, namely:
• Coagulation factor 5/8 C-terminal type domain (IPR000421)
◦ This domain forms part of a larger functional domain which promotes binding to anionic 
phospholipids on the surface of platelets and endothelial cells [65].
• CUB (IPR000859)
◦ The domain is found in extracellular and plasma membrane-associated proteins and is 
involved  in  a  variety  of  functions  including  tissue  repair,  axon  guidance  and 
angiogenesis, cell signalling, fertilisation, haemostasis, inflammation, receptor-mediated 
endocytosis, and tumour suppression [65]. The domain contains four cysteine residues 
that form two disulphide bridges [78]
• MAM domain (IPR000998)
◦ The MAM domain is found in cell surface proteins and it acts as an adhesion domain. 
• Galactose-binding domain-like (IPR008979)
◦ The  domain  binds  ligands  such  as  cell-surface-attached  carbohydrate  substrates  for 
NRP1-001
Figure 3.15: InterProScan result search for NRP1 protein-coding transcripts. 
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galactose oxidase, phospholipids on the outer side of the mammalian cell membrane for 
coagulation factor Va and membrane-anchored ephrin for the Eph family of receptor 
tyrosine kinases [65].
• Concanavalin A-like lectin/glucanase (IPR008985)
◦ Con A-like domains are important in cell recognition and examples of proteins that have 
the domain include the sex hormone-binding globulins which transport sex steroids in 
blood  and  regulate  their  access  to  target  tissues,  neurexins  which  are  expressed  in 
hundreds  of  isoforms on the  neuronal  cell  surface  where  they  may function  as  cell 
recognition molecules and sialidases that are found in both microorganisms and animals 
and  function  in  cell  adhesion  and  signal  transduction [65].  Other  proteins  include 
pentraxins PTX3 which is a TNFalpha-induced protein produced during inflammation 
by adipose cells [65].
• Neuropilin (IPR014648)
◦ This domain is the parent of the other domains identified for the transcript NRP1-001.
• Neuropilin-1, C-terminal (IPR022579)
NRP1-201 only  had  two  InterProScan  matches  that  are  also  found  in  NRP1-001,  namely  the 
Coagulation factor  5/8 C-terminal  type domain (IPR000421) and galactose-binding domain-like 
(IPR008979).  NRP1-005 had  four  matches,  Coagulation  factor  5/8  C-terminal  type  domain 
(IPR000421),  CUB  (IPR000859),  Galactose-binding  domain-like  (IPR008979)  and  Neuropilin 
(IPR014648). The lack of the CUB domain in the NRP1-201 transcript could potentially result in 
cancer as the transcript cannot bind semaphorins which are proteins with anti-tumour properties 
[78], whilst the loss of axon guidance and cell signalling functions could lead to T cell silencing as 
NRP1 has been shown to play a role in the stimulation of resting T cells by dendritic cells (DCs) 
[79].
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3.4.7 PRMT5
3.4.7.1 PRMT5 gene summary
Figure 3.16: PRMT5 gene summary modified from Ensembl. All the identified transcripts are 
protein-coding. Further analysis was performed using InterProScan, see section 3.4.7.4.
Normal T-cell suppression
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Almost all the transcripts were found expressed under T cell suppression conditions and are protein-
coding. Exceptions are PRMT5-006, a protein coding transcript, which was expressed under normal 
conditions, and  PRMT5-025, a T cell suppression transcript, which undergoes nonsense-mediated 
decay. Supporting evidence for the non-coding transcript is provided in section 3.4.7.3 whilst for the 
protein-coding transcripts further analysis was performed using InterProScan as shown in section 
3.4.7.4.
3.4.7.3 PRMT5 supporting evidence
The transcript,  according to EST evidence,  was found expressed in brain tissue (DA144868.1 , 
DC353315.1 and DC313238.1), lung and testis  (BI489755.1,  DC399129.1 and DC382817.1) and 
the small intestine (AK300863.1). Unfortunately the state under which the ESTs were found, could 
not be ascertained. 
3.4.7.4 PRMT5 protein functional analysis - InterProScan
The  protein  sequences  for  PRMT5-006,  PRMT5-017,  PRMT5-018 and  PRMT5-020 matched  2 
InterPro entries, namely:
• Protein arginine N-methyltransferase PRMT5 (IPR007857)
◦ The  protein  is  a  key  mitotic  regulator  and  is  involved  in  Jak  signalling. 
Methyltransferases are also involved in biosynthesis, signal transduction, protein repair, 
chromatin regulation as well as gene silencing [65].
PRMT5-025
Figure 3.17: Ensembl EST/cDNA supporting evidence for the PRMT5 transcripts. PRMT5-025 was 
found expressed in brain tissue (DA144868.1 , DC353315.1 and DC313238.1), lung and testis  
(BI489755.1, DC399129.1 and DC382817.1) and the small intestine (AK300863.1).
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• Protein arginine N-methyltransferase (IPR025799)
Unlike  the  previous  cases  discussed,  there  does  not  appear  to  be  any  difference  in  domain 
composition of PRMT5 proteins produced under normal versus T cell suppression conditions.
3.5 Transcript variations
We  then  looked  for  SNPs  within  the  isoforms  identified  in  section  3.4,  to  investigate  the 
contribution, if any, to T cell suppression. SNPs were selected, using dbSNP, based on the following 
criteria:  (1) should have phenotype data,  (2) the SNP can be located in the splice site,  i.e.  can 
influence the alternative splicing and thus the function of the gene, or (3) the SNP can be located in 
an splicing regulatory element (SRE) for example an exon splice enhancer (ESE) site. Genes that 
satisfied at least two of the criteria were further analysed. 
The gene  ATM  had SNPs that  satisfied the first  two criteria.  The gene,  located on 11q22-q23, 
encodes a protein that belongs to the PI3/PI4-kinase family of proteins and mutations are located all 
over the gene and are associated with ataxia telangiectasia as well as cancer [42]. One SNP that 
satisfied criteria 1. and 2. is CM063853, which, according to the public Human Gene Mutation 
Database (HGMD) (www.hgmd.org), is an A/T splice site variant in the ATM gene on chromosome 
11:108100050  (Figure 3.18).
Figure 3.18: The chromosome location of the A/T splice variant, CM063853. The variant is known 
to contribute to ataxia telangiectasia.
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The SNP is present in the T cell suppression-related transcripts  ATM-002 and  ATM-004 (retained 
introns) as well as other transcripts, refer to Figure 3.18. The T allele of CM063853 is associated 
with the increased risk of ataxia telangiectasia, an autosomal recessive disorder.
Another  SNP found  on  the  ATM-002 and  the  ATM-004 (retained  intron)  as  well  as  the  other 
transcripts is the rs1800054, which is a C/G variation on chromosome 11:108098576 (Figure 3.19). 
The variant results in missense mutations causing a ser49 to cys switch which has been linked to 
breast cancer susceptibility [43-45]. Missense mutations are known to change the sequence and 
structure of a protein leading to disease as a result of the altered splicing machinery process [76]. 
This non-synonymous SNP occurs in an exon splice enhancer (ESE) site recognised by the SR-
protein sc35 [58]. Since the SNPs, rs1800054 and CM063853, are found in both normal and T cell  
suppression transcripts they could have an effect under all  conditions,  although the SNP in the 
splice site may determine whether the longer T cell suppression  ATM-004 transcript is produced 
preferentially.
Like the SNPs identified for  ATM, the SNP for  MXI1 is present in transcripts found under both 
normal and T cell suppression conditions. The SNP rs14401, which is a C/T substitution,  is found 
downstream  of  the  gene  on  chromosome  10  at  position  112045171,  which  is  a  3'  UTR 
(Figure 3.20). This SNP occurs in an exon splice enhancer (ESE) site recognised by the SR-protein 
srp40 and the SNP causes a 'lose' effect on the site [15]. SNPs located in the 3' UTR could affect 
Figure 3.19: The chromosome location of the variant rs1800054. 
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MXI1 mRNA by destabilising  the  MXI1 transcripts  or  polyadenylation  site  selection  [77].  The 
variant results in cytotoxicity of lymphoblastoid cell lines (BLCLs) to CTL-1B9.
It seems that SNPs found within the splice sites and/or an SRE (splicing enhancers or silencers), do 
have an effect on alternative splicing. This modification can potentially lead to disease, as identified 
in this study, or may affect drug metabolism [88].
SNPs found in the other genes only satisfied one criteria, i.e. only had phenotype data. 
3.6 Functional analysis
In order to interpret the results biologically, we performed functional analysis using DAVID and the 
KEGG Mapper [74]. Enrichment analysis was performed using DAVID which allows for a large set 
of genes to be grouped into functionally related genes. The KEGG Mapper was used to map the 
genes onto relevant  pathways.  To understand the gene to  gene interactions,  interaction network 
analysis was performed using the STRING database.
Figure 3.20: The chromosome location of the variant rs14401, which is known to cause cytotoxicity  
of the lymphoblastoid cell lines.
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3.6.1. Enrichment analysis - DAVID
Using DAVID for enrichment analysis, using default parameters of count threshold of 2 and Ease 
score (p-value) of 0.1, results in 31 chart records for the set of 7 genes overlapping all the datasets. 
However,  if  we leave the count threshold at  2 (terms are meaningful if  more than one gene is 
associated with it) but lower the Ease score from 0.1 to 0.01 (the lower the score, the more enriched 
the terms are) we end up with 3 enrichment terms associated with the 7 genes passing the score, 
namely: alternative splicing (7 genes), the GO term cytoskeleton (4 genes) and disease mutation (4 
genes). The genes annotated to the term cytoskeleton are CALD1, LCK, ATM and VCL, whilst the 
disease mutation term applied to MXI1, LCK, ATM and VCL.
To further analyse the genes, we used DAVID's functional annotation table which allows one to 
view  a  lot  more  detail  about  the  individual  genes.  MXI1 is  inv lved  in  DNA binding,  has 
transcription repressor activity, acts as a T cell silencer as well as implication in neurofibrosarcoma 
and  prostate  cancer.  Low  levels  of  LCK have  been  implicated  in  severe  combined 
immunodeficiency (SCID) according to OMIM whilst ATM is part of a range of cancers including 
breast cancer, lymphoma as well as ataxia telangiectasia.
3.6.2 Pathway analysis - KEGG Mapper
The KEGG Mapper was used for pathway mapping of the 7 genes. The pathway analysis showed 
that ATM, LCK and NRP1 are involved in HTLV-1 infection (hsa05166). ATM has been shown to 
regulate T cell survival during HTLV-1 infection [66].  ATM and  LCK are represented in the NF-
kappa  B  signalling  pathways  (hsa04064).  CALD1 plays  a  role  in  vascular  muscle  contraction 
(hsa04270), while LCK is involved in natural killer cell mediated cytotoxicity (hsa04650) and T cell 
receptor signalling pathway (hsa04660). ATM is involved in apoptosis (hsa04210), it plays a role in 
the p53 signalling pathway (hsa04115) and is involved in transcriptional misregulation in cancer 
(hsa05202),  whilst  VCL is  involved  in  focal  adhesion  (hsa04510)  and  regulates  the  actin 
cytoskeleton (hsa04810).  NRP1 is involved in axon guidance (hsa04360) and has been shown to 
regulate T cell activation at the immune synapse [67,68]. PRMT5 forms part of the RNA transport 
pathway (hsa03013).
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3.6.3 Interaction analysis with STRING
In order to determine the level of interaction between the isoforms identified as occurring under T 
cell  suppression  conditions,  coexpression  analysis  was  performed  using  the  web-based  tool 
STRING (Search Tool for the Retrieval of Interacting Genes/Proteins) [62]. 
STRING was used to determine the level of interactions between the identified isoforms. Only T 
cell suppressed isoforms that have protein products were analysed. We not only examined the level 
of interaction between the isoforms but also between PIK3CA. PIK3CA is the catalytic subunit of 
the phosphatidyl-inositol-3-kinase (PI3K) and the signalling pathway is targeted by the measles 
virus (MV) in T cells. The pathway is important in a number of cellular processes such as cell  
growth, proliferation and survival, and interference of the signalling by MV results in the arrest of 
the cell cycle in T lymphocytes leading to T cell suppression.
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Using the multiple sequences tab to find the interactions, Figure 3.21 illustrates the output from the 
search. As already mentioned, only isoforms that have protein products were analysed using the 
tool.  Protein  sequences,  in  FASTA format,  of  the  following  transcripts  were  run  through  the 
program: PIK3CA,  LCK-010,  LCK-011,  VCL-202,  NRP1-001,  NRP1-005,  PRMT5-017,  PRMT5-
018, PRMT5-020 and PRMT5-014. As seen in Figure 3.20, the isoforms of the genes had some level 
of  interaction  with  the  PIK3CA except  for  PRMT5.  None  of  the  PRMT5 isoforms  had  any 
interaction with the kinase or the genes. The other genes shown in Figure 3.21 are genes predicted 
by the program to be functional partners of the kinase as well as the isoforms. 
Figure 3.21: STRING predicted gene interactions. The colour of each of the edges represents the  
type of  evidence that  exists  for  that  interaction:  a red line indicates the presence of  fusion  
evidence, a green line indicates neighbourhood evidence, a blue line indicates co-occurrence  
evidence,  a  purple line indicates  experimental  evidence,  a  yellow line indicates  text-mining  
evidence, a light blue line indicates database evidence, and a black line indicates co-expression  
evidence  [62].  The  genes  of  interest  were  ran  through  STRING  and  are  shown  to  have  
interaction  with  PI3K  with  the  exception  of  PRMT5.  The  rest  of  the  genes  are  predicted  
functional partners of the kinase and the isoforms.
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Table 3.4: STRING predicted functional partners of the isoforms.
Gene Description Interaction 
Isoform Score
CD4 CD4 molecule. Accessory protein for MHC class-II antigen/T cell 
receptor interaction. Regulates T cell activation. Induces the 
aggregation of lipid rafts.
LCK-006
LCK-010
LCK-011
LCK-202
0.999
PIK3R1 Phosphoinositide-3-kinase. It's the regulatory subunit 1 (alpha) and 
binds to activated (phosphorylated) protein-Tyr kinases, through its 
SH2 domain, and acts as an adapter, mediating the association of the 
p110 catalytic unit to the plasma membrane. Necessary for the 
insulin-stimulated increase in glucose uptake and glycogen synthesis 
in insulin-sensitive tissues.
LCK-006
LCK-010
LCK-011
LCK-202
0.994
VEGFA Vascular endothelial growth factor A. Growth factor active in 
angiogenesis, vasculogenesis and endothelial cell growth. Induces 
endothelial cell proliferation, promotes cell migration, inhibits 
apoptosis, and induces permeabilization of blood vessels. Binds to 
the VEGFR1/Flt-1 and VEGFR2/Kdr receptors, heparan sulfate and 
heparin. Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. 
Isoform VEGF165B binds to VEGFR2/Kdr but doesn't activate 
downstream signaling pathways, doesn't activate angiogenesis and 
inhibits tumor growth.
NRP1-001
NRP1-005
NRP1-201
0.999
PIK3CA 0.990
CD247 CD247 molecule. Probable role in assembly and expression of the 
TCR complex as well as signal transduction upon antigen triggering.
LCK-006
LCK-010
LCK-011
LCK-202
0.999
PTPRC Protein tyrosine phosphatase. Receptor type, C and is required for T 
cell activation through the antigen receptor. Upon T cell activation, 
recruits and dephosphorylates SKAP1 and FYN.
LCK-006
LCK-010
LCK-011
LCK-202
0.999
KDR Kinase insert domain receptor (a type III receptor tyrosine kinase). 
Receptor for VEGF or VEGFC. Has a tyrosine-protein kinase 
activity. The VEGF-kinase ligand/receptor signaling system plays a 
key role in vascular development and regulation of vascular 
permeability. In case of HIV-1 infection, the interaction with 
extracellular viral Tat protein seems to enhance angiogenesis in 
Kaposi's sarcoma lesions.
NRP1-001
NRP1-005
NRP1-201
0.999
PIK3CA 0.952
PXN Paxillin. Cytoskeletal protein involved in actin-membrane 
attachment at sites of cell adhesion to the extracellular matrix (focal 
adhesion).
LCK-006
LCK-010
LCK-011
LCK-202
0.657
VCL-001
VCL-202
VCL-204
0.999
CD8A CD8a molecule. Identifies cytotoxic/suppressor T-cells that interact 
with MHC class I bearing targets. CD8 is thought to play a role in 
the process of T cell mediated killing. CD8 alpha chains binds to 
class I MHC molecules alpha-3 domains.
LCK-006
LCK-010
LCK-011
LCK-202
0.999
SEMA3A Sema domain, immunoglobulin domain (Ig), short basic domain, 
secreted, (semaphorin) 3A. Induces the collapse and paralysis of 
neuronal growth cones. Binds to the complex neuropilin-1/plexin-1.
NRP1-001
NRP1-005
NRP1-201
0.999
LCP2 Lymphocyte cytosolic protein 2. Involved in T cell antigen receptor 
mediated signalling.
LCK-006
LCK-010
LCK-011
LCK-202
0.999
Table  3.4 highlights  the predicted  partners  together  with  their  descriptions  as  per  the STRING 
database. Also included in the table is a column that shows which of the identified isoforms have a 
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direct interaction with the predicted partners as well as a score value for the interactions. The score 
is a probabilistic confidence score, which is an estimate of how likely a given association describes 
a functional linkage between two proteins that is at least as specific as that between an average pair  
of proteins annotated on the same ‘map’ or ‘pathway’ in KEGG [62]. The various major sources of 
interaction/association data in STRING are benchmarked independently and a combined score is 
calculated which gives a higher score when more than one type of information supports a given 
interaction [62]. From the analysis, it is clear that LCK seems to have direct interactions (scores < 
0.99) with many predicted functional partners and the  PIK3CA. The predicted functional partners 
are involved in a range of T cell functions such as T cell activation (CD4, PTPRC), T cell antigen 
receptor  mediated  signalling  (LCP2),  T cell  mediated  killing  (CD8A)  as  well  as  assembly  and 
expression of the T cell receptor  TCR (CD247). NRP1 and PIK3CA have direct relationship with 
VEGFA, KDR and SEMA3A. VEGFA plays a role in cell proliferation, cell migration and inhibition 
of apoptosis;  KDR is involved in vascular regulation via its tyrosine-protein kinase activity and 
SEMA3A has a negative effect on neuronal growth cones.  VCL is associated with  PXN, which is 
involved in focal adhesion just like VCL.
The results confirm that there is a functional connection between the final gene list we identified as 
being involved in T cell suppression through alternative splicing. Compared to the controls, i.e. the 
isoforms  found  under  the  normal  conditions,  the  isoforms  found  under  the  T cell  suppression 
conditions  are  polymorphic  in  nature  due  to  alternative  splicing.  This  led  to  loss  of  domains 
important in the phosphorylation of downstream targets, which we think might be one of the causes 
of gene silencing.
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CHAPTER 4
4.1 DISCUSSION
MV induced immunosuppression occurs  as a  result  of the interference of PI3K/AKT signalling 
leading to T cell suppression, and the interference has been shown to promote the production of 
alternatively  spliced  protein  isoforms  such  as  the  SIP100,  an  alternatively  spliced  isoform  of 
SHIP145 [35]. These alternatively spliced protein products are thought to cause T cell suppression 
by interfering with the signalling pathways that are important in T cell activation [35]. This project 
addressed the question of whether more of these alternatively spliced isoforms exist, and could thus 
be potential genetic markers to be used in identifying T cell suppression.
A total of 9 microarray experiments were identified and further analysed using GEO2R, a gene 
expression analysis tool. GEO2R is a web-based application that uses Limma to analyse the data 
and allows one to download the R script used to run the analysis. Although the tool is useful in that 
a large number of GEO data can be analysed, there are some weaknesses to the system one must be  
aware of:
• GEO allows data that is processed and normalised by different methodologies
◦ Submitters to the GEO repository employ different methodologies when processing and 
normalising their data. GEO2R takes the values as they are and identifies differentially 
expressed genes, unless if no log transformation has been applied to the values, then it 
will log transform the values.  
• Not all experiments are analysed by GEO2R
◦ GEO2R works  only on data  tables  (i.e  have values  that  can be used to  identify the 
differentially  expressed  genes).  Data  from high-throughput  sequencing  and  genome-
array tiling cannot be analysed by the system.
◦ Data should only use one series.
◦ Works on sample size limit of 255.
◦ A  processing time limit of 10 minutes is allowed on jobs.
Nevertheless, the tool was used, and the following genes were found to have different isoforms 
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produced under normal vs. T cell suppression conditions:  ATM, CALD1, LCK, VCL, MXI1, NRP1 
and  PRMT5.  ATM,  PRMT5 and  VCL overlapped  with  the  differentially  regulated  list  of  the 
GeneChip  exon array  whilst  CALD1,  MXI1,  NRP1 and  LCK overlapped  with  the  alternatively 
spliced list. Genes such as  CD44,  BRCA1,  FGF1 and PSEN1 only had isoforms found under one 
condition only, either normal or T cell suppression but not both. This is interesting as these genes'  
alternative  splicing  has  been well  studied  [49].   The  list that  showed genes  that  had  isoforms 
produced under one condition only,  also included the gene  INPPL1 which is  part  of the  SHIP 
family of genes. 
The probes  representing  the  different  isoforms for  genes  LCK,  MXI1,  VCL and  PRMT5,  were 
mostly significantly expressed with p-values <0.05.  Probes representing  ATM,  CALD1 and  NRP1 
had  p-values  >0.05.  The  Benjamini  &  Hochberg  false  discovery  rate method  was  selected  in 
GEO2R to calculate the p-values as it provides a good balance between discovery of statistically 
significant  genes and limitation of  false  positives  [57].  Ensembl was used to  identify the gene 
transcripts represented by the probes. It was interesting to note that for three of the genes whose 
transcripts were found to be expressed under either T cell suppression or normal conditions, the 
biotype was retained introns (ATM and CALD1), nonsense-mediated decay (CALD1) and processed 
transcripts (MXI1). Both the nonsense-mediated and processed transcripts are non-coding with the 
former preventing expression of truncated proteins and the latter does not have an open reading 
frame [59]. Retained introns are known to cause in frame stop-codons and result in translation of 
prematurely terminated proteins causing nonsense-mediated mRNA decay (NMD) [1]. Therefore 
for these three genes, under at least one of the conditions (either normal or T cell suppression), no 
actual  protein  product  is  made.  Interestingly  the  SIP110, found  to  be  expressed  under  T  cell 
suppression conditions, also has a retained intron.   Please see Figure 4.1, the retained intron is 
circled in red.
Figure 4.1: SIP110 is a retained intron [50]. Exon 5 + 6 are constitutively spliced in SHIP145.  
SIP110 is an alternatively spliced form of SHIP145 which has intronic sequences.
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It seems that intron retention by the alternative splice sites of the identified isoforms, forms the 
basis  of  pathogen-mediated  T  cell  suppression  and  could  potentially  be  used  as  biomarkers. 
Biomarkers are biologic molecules that are used to indicate the state and progression of a disease 
[86]. A good biomarker should be easy to detect at an early stage and should be measurable across 
different populations [86]. In this study, supporting evidence in the form of EST/cDNAs for the 
non-coding transcripts was examined and as mentioned in chapter 1, one of the challenges with 
using ESTs is poor annotation. The source of the EST/cDNA was easily identified for this study but 
the condition under which it was found was difficult to ascertain. The reader must bear in mind 
these challenges. The EST/cDNA supporting evidence for the identified non-coding isoforms ATM-
002, ATM-004, CALD1-004 and PRMT5-025 could potentially be used as biomarkers as they can be 
detected clinically using RT-PCR but do not meet all the criteria that constitute a good biomarker as 
we  do  not  know under  which  condition  the  EST/cDNAs were  found.  On  the  other  hand,  the 
EST/cDNA supporting evidence for the identified non-coding isoforms  MXI1-003 and  MXI1-012 
had better annotation, as the cDNA BC016678.1 was found expressed in skin tissue with melanotic 
melanoma and could thus make a better candidate for a biomarker for T cell suppression. Further 
studies would need to be performed to determine not only the conditions but the stage of the disease 
under which the EST/cDNAs are found.
For genes that had protein-coding transcripts expressed under both normal and T cell suppression 
conditions,  protein  functionality  was examined using InterProscan [65].  The isoform  LCK-010, 
found expressed under T cell  suppre sion conditions,  was found to lack the protein kinase-like 
domain  which  was  found present  in  the  LCK-202 and  LCK-006 both  expressed  under  normal 
conditions. The protein kinase-like domain plays an important role in the phosphorylation of other 
protein targets and it seems that the loss of the domain contributes to the immunosuppression of the 
T cells. Further evidence in support of the importance of the protein kinase-like domain's role in 
immunosuppression can be seen in the  LCK-202  transcript.  LCK-202, found expressed in normal 
conditions, lacks the SH2 and the SH3 domains but has the protein kinase-like domain. The SH2 
and SH3 domains are both adaptors that play a role in signalling protein-protein interactions [87]. 
Another gene that had interesting results from the InterProScan was VCL.  VCL-001 and VCL-204 
both expressed under normal conditions, were found to have all 7 motifs present on the transcripts. 
In the case of the VCL-202 found expressed under T cell suppression conditions, a lack or loss of 
the  conserved  motifs  seems  to  contribute  to  the  pathogen-mediated  immunosuppression.  The 
proline-rich motifs 1 and 2 seem to be crucial in both the normal and diseased conditions, as they 
were  found  present  on  all  the  VCL transcripts.  The  proline-rich  regions  play  a  role  in  signal 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
81
transduction, antigen recognition, cell-cell communication as well as cytoskeletal organization [75]. 
The identified protein-coding isoforms could potentially be used as biomarkers as antibodies that 
bind specifically to the protein isoforms could be manufactured and used to detect the isoforms 
using  immunohistochemical  techniques  such as  enzyme-linked immunosorbance  assay  (ELISA) 
and RT-PCR [86].
We performed further analysis on the identified isoforms to investigate the variations. SNPs were 
selected using dbSNP based on phenotype data, location within a splice site, or the mutation results 
in an SRE. Two SNPs for ATM which are SNP CM063853 (A/T) and rs1800054 (C/G) passed the 
criteria and are known to cause ataxia telangiectasia as well as breast cancer respectively [42-45]. 
The SNP is found in an exon splice enhancer (ESE) site for the SR-protein sc35 [59]. For MXI1, the 
SNP which passed the criteria is the SNP rs14401 (C/T) which is found downstream of the gene at 
the 3' UTR. 
There seems to be evidence, albeit very little in the form of only 3 SNPs belonging to the 2 genes, 
that suggests that the isoforms identified in this study to regulat  T cell suppression are polymorphic 
[86].  Techniques  such as  PCR and  ELISA could  be  used  as  well  to  detect  these  polymorphic 
isoforms/biomarkers.
As the aim of the study was to identify the genes and their alternatively spliced products that occur 
as  a  result  of  PI3K  interference,  an  interaction  analysis  with  PI3K  was  performed  using  the 
STRING  database.  The  interactions  between  the  protein-coding  isoforms  and  PIK3CA were 
examined. PIK3CA is the catalytic subunit of the phosphatidyl-inositol-3-kinase (PI3K) and the 
signalling pathway is targeted by the measles virus (MV) in T cells, which results in the arrest of the 
cell cycle leading to T cell suppression. The program predicted functional partners for the isoforms 
and LCK had direct interactions (scores < 0.99) with many predicted functional partners as well as 
the PIK3CA. The predicted functional partners that LCK had relationships with, are involved in T 
cell activation (CD4, PTPRC), T cell antigen receptor mediated signalling (LCP2), T cell mediated 
killing (CD8A) and assembly and expression of the T cell  receptor (TCR) (CD247).  NRP1 and 
PIK3CA have a direct relationship with  VEGFA,  KDR and  SEMA3A.  VEGFA plays a role in cell 
proliferation,  cell  migration and inhibition of apoptosis;  KDR is involved in vascular regulation 
through its tyrosine-protein kinase activity and SEMA3A has a negative effect on neuronal growth 
cones. VCL is associated with PXN, which is involved in focal adhesion just like VCL.  
It seems that the identified transcripts do not act alone, but rather in cooperation with other co-
receptors. Perhaps a biomarker could be designed in such a way as to detect not only LCK and VCL 
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isoforms  in  this  case,  but  also  their  functional  partners  as  predicted  by  STRING.  This  could 
potentially increase the accuracy with which to detect pathogen-mediated T cell suppression. As an 
example, the LCK transcript was predicted to interact with the the co-receptors CD8A, CD247 and 
CD4. This was not surprising as these co-receptors are known to play a role in the TCR [80].  It 
appears that co-receptor signalling, kinase signalling, conservation of motifs as well as assembly of 
the TCR play an important role in T cell suppression. 
4.2. CONCLUSION
The  microarray  experiments  that  were  used  to  support  the  genes  identified  as  causing  T  cell 
suppression, involved an investigation into the effect of pathogens (MV, HCMV, HIV and RV) on 
monocytes or PBMCs. According to Avota et. al (2006) the retained intron isoform, SIP110, was 
found  expressed  under  T  cell  suppression  conditions  [50].  In  this  study,  we  also  identified 
alternatively  spliced  isoforms  expressed  under  T  cell  suppression  conditions  that  had  intronic 
sequences and could potentially be used as biomarkers. The lack of properly annotated EST/cDNAs 
for the identified non-coding isoforms, with the exception of MXI1, will require further studies to be 
performed to better ascertain under what conditions and what stage in the disease the EST/cDNAs 
were found. 
The study also discovered that protein-coding transcripts found under T cell suppression conditions, 
seem to lack the protein kinase-like domain and suffer from a loss of conserved motifs. It would 
seem that the presence of the proline-rich regions in both conditions, normal and T cell suppression, 
is crucial for the functioning of the identified isoforms. 
The protein interactions analysis revealed that cooperation of the identified isoforms together with 
the co-receptors is crucial in T cell suppression. How the T cell suppressed isoforms interact with 
the co-receptors, has to be studied further. The protein interaction database, STRING, does not work 
on splicing isoforms but rather reduces the protein isoforms to a single protein per gene by choosing 
the longest known isoform [82]. This has unfortunately resulted in only protein interactions at the 
gene level being analysed in this study and not at the isoform level. A possible future study would  
require an analysis of the impact of alternative splicing on the protein interactions as well as protein 
scaffolding. 
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APPENDIX A: Genes predicted to be involved in T cell suppression 
ABCB1 ANTXR1 BDP1 CCL3L3 CHD8 CXCL13 E2F1 FAP
ABCC1 ANXA1 BEST1 CCL4 CHEK1 CXCL3 E2F3 FAS
ABCC2 ANXA11 BFSP1 CCL5 CHEK2 CXCL5 E2F4 FASLG
ABCC8 ANXA3 BGLAP CCL7 CHKA CXCR3 E2F5 FASN
ABCD3 ANXA5 BID CCL8 CHN1 CXCR4 E2F6 FBLN1
ABCG1 ANXA7 BIN1 CCNA1 CHRD CXCR6 E4F1 FBLN5
ABCG2 APAF1 BIRC2 CCNA2 CHRM2 CYB5A EAF2 FBXO32
ABHD5 APBA2 BIRC3 CCNB1 CHRM3 CYBA EBAG9 FBXW7
ABI1 APBA3 BIRC7 CCND1 CHUK CYBB ECE1 FBXW8
ABL1 APC BLM CCND2 CIITA / MHC2TA CYCS EDN1 FCER2
AC012652.1 APEX1 BLNK CCND3 CISH CYP11A1 EDN3 FCGR1A
ACAA1 API5 BLOC1S2 CCNE1 CKB CYP11B1 EDNRA FCGR2A
ACACA APLN BLVRB CCNH CKM CYP11B2 EDNRB FCGR2B
ACAT1 APLNR BMI1 CCNT1 CLCN1 CYP19A1 EEF2K FCGR3A
ACAT2 APOA1 BMP2 CCR1 CLCN3 CYP1A1 EFNA1 FDFT1
ACD APOA2 BMP4 CCR3 CLDN10 CYP1A2 EGF FDPS
ACE APOB BMPR1A CCR4 CLDN2 CYP1B1 EGFR FDXR
ACHE APOBEC3F BMPR2 CCR6 CLEC4A CYP21A2 EGLN1 FES
ACLY APOBEC3G BNIP1 CCR8 CLIC4 CYP24A1 EGLN2 FGA
ACO1 APOC3 BNIPL CCR9 CLU CYP2A6 EGLN3 FGF1
ACP5 APOE BPI CCT6A CMA1 CYP2B6 EGR1 FGF10
ACPP APPL1 BRAF CD163 CNBP CYP2C19 EGR2 FGF19
ACSL1 APRT BRCA1 CD1A CNN1 CYP2E1 EHHADH FGF23
ACTA1 AQP1 BRCA2 CD2 CNP CYP2J2 EHMT2 FGF4
ACTG2 AQP4 BRD4 CD200 CNR1 CYP3A4 EI24 FGF5
ACTN1 AQP7 BRD7 CD200R1 CNR2 CYP3A5 EIF2AK1 FGF7
ACTN2 AQP8 BRMS1 CD209 CNTF CYP3A7 EIF2AK2 FGF8
ACTN3 AR BTG3 CD244 CNTN1 CYP4A11 EIF2AK3 FGFR1
ACTN4 AREG BTK CD247 CNTN2 DAB1 EIF2C2 FGFR2
ACTR2 ARF6 BTRC CD274 COL15A1 DAB2 EIF3A FGFR3
ACVR1B ARG1 C11ORF58 CD28 COL18A1 DACH1 EIF4A1 FGFR4
ACVR2A ARG2 C19ORF2 CD33 COL1A1 DAO EIF4E FGG
ACVRL1 ARHGAP24 C1QBP CD34 COL2A1 DAPK1 EIF4EBP1 FGR
ADA ARHGAP5 C2 CD36 COL4A1 DARC EIF4G1 FHIT
ADAM15 ARHGDIA C3AR1 CD38 COL4A2 DAXX EIF5A FHL1
ADAM17 ARHGDIB C4BPB CD3D COL4A3 DBN1 EIF6 FIBP
ADAMTS4 ARHGEF2 C6ORF25 CD4 COL4A3BP DCN ELAC2 FKBP1A
ADAMTS5 ARID4A CA2 CD40 COL4A4 DCT ELANE FKBP1B
ADAR ARMC10 CA3 CD40LG COL4A6 DCTN1 ELAVL1 FKBP4
ADC ARNT CA6 CD44 COPS8 DCX ELF1 FLI1
ADCY1 ARNTL CABIN1 CD46 COX4I2 DCXR ELF3 FLNA
ADCY10 ARRB1 CABP1 CD55 COX5A DDB2 ELF4 FLT1
ADCY2 ARRB2 CACNA1B CD58 COX8A DDC ELK1 FLT3
ADCYAP1 ARSH CACNA1I CD59 CPOX DDIT3 ELN FLT3LG
ADCYAP1R1 ASAH1 CACNA2D2 CD68 CPS1 DDOST EMB FLT4
ADD1 ASPH CACYBP CD7 CPSF4 DDR1 ENG FMN1
ADIPOQ ATF1 CAD CD74 CPT1A DDX3X ENO1 FMR1
ADIPOR1 ATF2 CADM1 CD79A CR1 DDX5 ENO2 FOLH1
ADK ATF3 CALCA CD79B CRABP2 DDX58 ENO3 FOLR1
ADM ATF4 CALCR CD80 CRAT DEFB1 ENPP1 FOLR2
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ADORA1 ATF6 CALCRL CD82 CRB1 DES ENPP2 FOS
ADORA2A ATM CALD1 CD83 CREB1 DFFB ENTPD1 FOSB
ADORA2B ATN1 CALM1 CD86 CREB3 DFNA5 EP300 FOSL1
ADORA3 ATP1A1 CALR CD8A CREBBP DGKB EPAS1 FOXK1
ADRBK1 ATP1A2 CALU CD8B CREM DGKD EPB41L1 FOXM1
AEBP1 ATP1B2 CAMK2A CD9 CRH DGKQ EPB41L2 FOXN3
AES ATP1B3 CAMK2D CDC14A CRHR1 DGUOK EPB41L3 FOXO1
AFP ATP2A2 CAMK2G CDC25A CRHR2 DHODH EPB49 FOXO3
AGAP2 ATP2A3 CAMK2N2 CDC25C CRK DICER1 EPCAM FOXO4
AGER ATP2B1 CAMK4 CDC27 CRKL DIO2 EPHA1 FOXP3
AGPAT2 ATP2C1 CAMKK2 CDC42 CRP DKK1 EPHA2 FPR1
AGRN ATP5A1 CAMP CDC6 CRY1 DLC1 EPHA3 FRS2
AGTR1 ATP6V0A2 CANT1 CDC7 CRYAB DLG4 EPHB2 FSCN1
AGTRAP ATP6V1A CANX CDH1 CS DLK1 EPHB6 FSHB
AHCY ATP7A CAPN1 CDH11 CSDA DLL1 EPHX2 FSHR
AHR ATP7B CAPN10 CDH2 CSF1 DMBT1 EPM2A FST
AHSG ATR CAPN2 CDH5 CSF1R DMD EPO FTL
AICDA ATRN CAPRIN2 CDK2 CSF2 DMP1 EPOR FURIN
AIF1 ATRX CAPZA1 CDK4 CSF2RA DMPK EPRS FUT3
AIFM1 ATXN1 CARD8 CDK5 CSF3 DMTF1 EPS15 FUT8
AK1 ATXN3 CASP1 CDK5R1 CSF3R DNAJA1 ERBB2 FYN
AKAP12 AURKA CASP10 CDK5R2 CSH1 DNAJA3 ERBB2IP G6PC
AKR1A1 AURKB CASP2 CDK6 CSK DNAJB1 ERBB3 G6PD
AKR1C1 AXIN1 CASP3 CDK7 CSN2 DNAJB6 ERBB4 GAB1
AKR1C3 AXL CASP4 CDK9 CSNK1A1 DNASE1 ERCC1 GAB2
AKT1 B2M CASP6 CDKN1A CSNK2A1 DNM3 ERCC5 GABBR1
AKT2 B3GALTL CASP7 CDKN1B CSNK2A2 DNMT1 ERP29 GABPB1
AKT3 B3GAT1 CASP8 CDKN1C CSNK2B DNMT3A ESPN GABRG2
ALCAM BACE1 CASP9 CDKN2A CTBP1 DNMT3B ESR1 GAD1
ALDH2 BACE2 CASR CDKN2B CTBP2 DNTT ESR2 GAD2
ALDH7A1 BACH1 CAST CDKN3 CTCF DOCK4 ESRRB GADD45A
ALDH9A1 BAD CAT CEACAM1 CTLA4 DOK1 ETS1 GADD45B
ALK BAIAP2L1 CAV1 CEACAM5 CTNNA1 DPP4 ETS2 GADD45G
ALOX12 BAK1 cav2 CEBPA CTNNB1 DPYD ETV6 GALC
ALOX15 BARD1 CBFB CEBPB CTNND1 DRD2 ETV7 GALE
ALOX15B BAX CBL CEBPD CTSB DSC1 EWSR1 GALT
ALOX5 BBS9 CBS CES1 CTSC DSG1 EXO1 GANAB
ALPL BCAR1 CBX2 CES2 CTSD DSG2 EZH2 GAP43
ALPP BCCIP CBX5 CETP CTSE DSG3 EZR GAPDH
ALS2 BCHE CCDC50 CFD CTSG DSP F10 GAS6
AMACR BCKDHB CCK CFDP1 CTSL1 DUSP1 F2 GAST
AMBP BCL2 CCKBR CFH CTTN DUSP13 F2R GATA1
AMFR BCL2A1 CCL1 CFL1 CUL7 DUSP4 F2RL1 GC
AMHR2 BCL2L1 CCL18 CFLAR CUX1 DUSP5 F8 GCG
AMOT BCL2L11 CCL2 CFTR CX3CL1 DUSP6 FABP3 GCH1
AMPD3 BCL3 CCL23 CGA CX3CR1 DUT FABP4 GCK
ANAPC7 BCLAF1 CCL25 CGB5 CXADR DYNC1H1 FADD GDF15
ANGPT2 BCR CCL27 CHAF1A CXCL1 DYNC2H1 FAM49B GDNF
ANK1 BDKRB2 CCL3 CHAT CXCL11 DYNLL1 FANCA GFAP
ANPEP BDNF CCL3L1 CHD7 CXCL12 DYRK1A FANCD2 GFM1
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GFPT1 HDAC6 IGFBP5 KCNJ2 LYN MSR1 NPHS1 PDE4A
GFRA2 HDAC9 IGFBP6 KCNN2 LYST MSRA NPM1 PDE4B
GGCX HDGF IKBKB KCNN3 M6PR MST1R NPPA PDE5A
GGT1 HEMGN IKBKG KCNN4 MADD MSTN NPPB PDE7A
GH1 HES6 IKZF1 KCNQ1 MAEA MT1A NPPC PDGFA
GHR HFE2 IKZF2 KCNQ2 MAG MT2A NPR1 PDGFB
GHRH HGF IL10 KCNQ4 MAGED1 MT3 NPR3 PDGFC
GHRHR HGFAC IL11 KCNQ5 MALT1 MTA1 NPTN PDGFD
GHRL HGS IL12A KDR MAN2B1 MTDH NPY PDGFRA
GJA1 HHIP IL12RB1 KEAP1 MAOA MTF1 NPY5R PDGFRB
GJA5 HIC1 IL12RB2 KHDRBS1 MAP1B MTHFR NQO1 PDIA3
GJB2 HIF1A IL13 KHK MAP1LC3A MTMR14 NR0B1 PDK1
GK HIF3A IL13RA1 KIAA0101 MAP1S MTMR3 NR0B2 PDK2
GLI1 HIPK2 IL13RA2 KIF1B MAP2 MTNR1A NR1H2 PDK4
GLI2 HK1 IL15 KIF5B MAP2K1 MUC1 NR1H3 PDLIM2
GLI3 HK2 IL15RA KISS1 MAP2K2 MUC15 NR1H4 PDLIM3
GLO1 HLA-B IL17A KISS1R MAP2K3 MUC20 NR1I2 PDLIM4
GLRX HLA-G IL17F KIT MAP2K4 MUC4 NR1I3 PDLIM5
GLRX2 HLCS IL17RA KITLG MAP2K6 MUSK NR2C1 PDLIM7
GLS HMBS IL18 KL MAP2K7 MUTYH NR2C2 PDPK1
GLUL HMGA1 IL19 KLF10 MAP3K1 MVP NR2E3 PDPN
GNA13 HMGA2 IL1A KLF2 MAP3K14 MXD3 NR3C1 PEMT
GNAI1 HMGB1 IL1B KLF6 MAP3K4 MXI1 NR3C2 PENK
GNAO1 HMGCR IL1R1 KLK3 MAP3K5 MYB NR4A1 PEPD
GNAS HMMR IL1RAP KLK8 MAP3K7 MYBL2 NR5A1 PER1
GNB2 HMOX1 IL1RL1 KLRC1 MAP3K8 MYCN NR5A2 PER2
GNB2L1 HMOX2 IL1RN KLRD1 MAP4 MYD88 NRAS PF4
GNLY HNF1A IL2 KNG1 MAP4K1 MYF5 NRF1 PFKFB3
GNRH1 HNF1B IL21 KRAS MAP6 MYH10 NRG1 PFN1
GNRHR HNF4A IL24 KRT14 MAPK1 MYH11 NRIP1 PGF
GOT2 HNRNPA1 IL25 KRT18 MAPK10 MYH14 NRP1 PGK1
GP1BA HNRNPA2B1 IL2RA KRT19 MAPK11 MYH9 NRP2 PGR
GPD1 HNRNPK IL3 KRT7 MAPK12 MYL2 NSUN5 PHB
GPI HNRNPR IL32 KRT8 MAPK14 MYL4 NTF3 PHKA2
GPR56 HOMER1 IL4 L1CAM MAPK3 MYLK NTM PI3
GPRC6A HOXA10 IL4R LAG3 MAPK8 MYOC NTRK1 PIAS2
GPS1 HOXA3 IL5 LALBA MAPK9 MYOCD NTRK2 PIAS3
gpt HOXA9 IL6 LAMA1 MAPKAP1 MYOD1 NTRK3 PIGP
GPT2 HP IL6R LAMA3 MAPKAPK2 MYOG NTS PIK3C2A
GPX4 HPD IL6ST LAMB1 MAPKAPK5 MYOM1 NUB1 PIK3C3
GRB10 HPN IL7 LAMC2 MAPRE2 NAB2 NUDT1 PIK3CA
GRB2 HPR IL7R LAMP2 MAPT NAGLU NUDT10 PIK3CB
GRB7 HPSE IL8 LAP3 MAT1A NAIP NUDT6 PIK3CG
GREM1 HPX ILF3 LBR MATK NAT1 NUMB PIK3IP1
GRIA1 HRAS ILK LCK MATN1 NBL1 OAT PIK3R1
GRIA2 HRH2 IMPA1 LCN1 MAX NBN OCLN PIK3R2
GRIA3 HRH3 IMPDH1 LCP1 MBD1 NCAM1 OGDH PIM1
GRIA4 HRH4 ING1 LDHA MBD2 NCF1 OGG1 PIP5KL1
GRIN1 HSD11B1 ING2 LDHB MBD3 NCF2 OLR1 PITPNA
GRIN2A HSD11B2 INHA LDLR MBL2 NCK1 ONECUT1 PITX1
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GRIN2B HSD17B2 INPPL1 LECT1 MC2R NCL OPN4 PITX2
GRIP1 HSF1 INS LEF1 MCC NCOA1 OPRD1 PKD1
GRK4 HSP90AA1 INSR LEP MCF2 NCOA2 OPRM1 PKIB
GRM1 HSP90AB1 INTS6 LEPRE1 MCL1 NCOA3 ORAI1 PKLR
GRM2 HSP90B1 IRAK1 LGALS1 MCM7 NCOA4 ORC1 PKM2
GRM5 HSPA14 IRAK3 LGALS12 MDM2 NCOA6 OSBPL8 PLA2G1B
GRP HSPA1A IRF1 LGALS3 MDM4 NCOR1 OSM PLA2G2A
GSK3B HSPA4 IRF2 LGALS3BP MECP2 NCOR2 OTC PLA2G4A
GSN HSPA5 IRF3 LGALS4 MED1 NCR3 OTOF PLA2G5
GSR HSPA8 IRF7 LGALS9 MED23 NDRG2 OTUD5 PLA2G6
GSTA4 HSPA9 IRS1 LGI1 MEF2A NEDD4 OTX2 PLA2G7
GSTM1 HSPB1 ITCH LGMN MEFV NEDD4L OXTR PLA2R1
GSTP1 HSPE1 ITGA2 LHCGR MEIS1 NEDD8 P4HTM PLAGL1
GTF2A1 HSPG2 ITGA2B LHX3 MEN1 NEK2 PA2G4 PLAT
GTF2B HTATIP2 ITGA3 LIF MEST NES PABPC4 PLAU
GTF2F1 HTR2A ITGA4 LIFR MET NEU1 PABPN1 PLAUR
GTF2I HTR2B ITGA5 LIG4 METAP2 NEUROG3 PACRG PLCB1
GUCA2A HTR2C ITGA6 LILRA3 MGAT3 NF1 PADI1 PLCB3
GUK1 HTR3A ITGAL LILRB1 MID1 NF2 PAEP PLCB4
GUSB HTR4 ITGAM LILRB2 MITF NFATC1 PAFAH1B1 PLCE1
GYS1 HTRA1 ITGAV LILRB3 MKI67 NFATC2 PAICS PLCG1
GYS2 HTT ITGB1 LILRB4 MKKS NFE2 PAK1 PLCG2
GZMA HUWE1 ITGB2 LIMK1 MKNK1 NFE2L2 PAK2 PLCL1
GZMB HYAL1 ITGB3 LIN28B MLH1 NFIC PAK4 PLCZ1
H1F0 HYAL2 ITGB3BP LIPA MLL NFKB1 PAM PLD1
HADHA HYOU1 ITGB4 LIPC MME NFKB2 PAPSS2 PLD2
HADHB IAPP ITIH4 LIPE MMP1 NFKBIA PARD3 PLEK
HAGH IBSP ITM2A LIPF MMP11 NGF PARK2 PLEKHO1
HAMP ICAM1 ITPA LIPG MMP12 NGFR PARP1 PLG
HAPLN1 ICOS ITPR1 LMNA MMP13 NGLY1 PAWR PLK1
HAS1 ICOSLG IVL LMNB1 MMP16 NID1 PAX2 PLK3
HAS2 ID1 JAG1 LONP1 MMP2 NIPBL PAX3 PLOD2
HAS3 ID2 JAK1 LOX MMP3 NISCH PAX5 PLOD3
HBB ID3 JAK2 LOXL2 MMP7 NKX2-1 PAX6 PLP1
HBEGF IDH1 JAK3 LPA MMP9 NKX3-1 PAX7 PLS3
HBG1 IDH2 JMJD6 LPAR1 MOG NLRC4 PAX8 PLSCR1
HBG2 IDO1 JPH4 LPAR3 MPG NLRP1 PBK PLUNC
HCFC1 IDS JUN LPL MPO NLRP3 PBX1 PMAIP1
HCLS1 IFI16 JUNB LPO MPP1 NLRP7 PC PML
HCN1 IFNAR1 JUND LPXN MPZ NME4 PCBP2 PMS2
HCN2 IFNAR2 JUP LRP1 MR1 NNAT PCGF6 PNCK
HCN4 IFNG KAT2B LRP8 MRC2 NOD2 PCK2 PNKD
HCRT IFT81 KAT5 LRPAP1 MRE11A NODAL PCMT1 PNLIP
HCRTR1 IGF1 KBTBD10 LRRK2 MSC NOS1 PCNA PNPLA8
HCRTR2 IGF1R KCND1 LSP1 MSH2 NOS2 PCNT POLB
HDAC1 IGF2BP1 KCND2 LSS MSH6 NOS3 PCSK1 POMC
HDAC2 IGFALS KCNE1 LTA MSI1 NOTCH1 PDCD1LG2 POMT1
HDAC3 IGFBP1 KCNH2 LTB MSLN NOTCH3 PDCD4 PON1
HDAC4 IGFBP3 KCNJ1 LTF MSMB NOX1 PDE2A POR
HDAC5 IGFBP4 KCNJ11 LY75 MSN NOX4 PDE3B PORCN
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
93
PRKCB RANBP2 SAFB SLC6A12 STX2 TNFRSF25 VCAN
PRKCD RAP1A SALL1 SLC6A2 STXBP1 TNFRSF4 VCL
PRKCE RAPGEF3 SAT1 SLC6A3 SUFU TNFRSF8 VCP
PRKCG RARA SCARA3 SLC6A4 SULT1E1 TNFRSF9 VDAC1
PRKCI RARB SCARB1 SLC7A1 SULT2A1 TNFSF10 VDR
PRKCZ RARG SCARB2 SLC8A1 SUMO1 TNFSF11 VEGFC
PRKD1 RARS SCARF1 SLC9A1 SUZ12 TNFSF13 VGF
PRKD2 RASA1 SCARF2 SLC9A2 SVIL TNFSF13B VHL
PRKD3 RASA2 SCD SLC9A3 SYK TNFSF14 VIM
PRKDC RASA4 SCGB1A1 SLC9A3R1 SYNM TNFSF15 VIP
PRKG1 RASGRF1 SCN5A SLCO4A1 SYNPO TNFSF18 VIPR1
PRKG2 RASSF1 SCN7A SLPI SYNPO2 TNNI3 VPS24
PRL RASSF5 SCNN1A SMAD2 SYP TNNT1 VWCE
PRLR RB1 SCNN1B SMAD3 SYVN1 TNS1 WAS
PRMT1 RB1CC1 SCP2 SMAD4 T TOB1 WASF2
PRMT5 RBBP4 SCRIB SMAD6 TAC1 TOM1 WDR26
PRNP RBBP6 SCYL1 SMAD7 TAC4 TOP2A WEE1
PRODH RBBP8 SDC1 SMARCA2 TACR1 TP53 WHSC1
PROK1 RBL1 SDC2 SMARCA4 TAF1 TP53BP1 WIPF1
PROM1 RBM3 SDCBP SMARCB1 TAF6 TP53BP2 WNK1
PROS1 RBM5 SDHB SMARCD3 TAF9 TP53I3 WNT1
PROX1 RBMX SEC14L2 SMC1A TANK TP63 WNT2
PRSS2 RBP1 SELE SMC3 TAT TP73 WNT3A
PRSS3 RBP2 SELL SMG1 TAZ TPH1 WRN
PSAT1 RBP3 SELP SMOX TBP TPI1 WWC1
PSEN1 RBP4 SEMA3B SMPD1 TBX21 TPM1 WWOX
PSEN2 RBPJ SEMA3F SMPD2 TBX3 TPM3 XAF1
PSMA1 RCAN1 SEPT4 SMTN TBXA2R TPO XBP1
PSMA3 RDX SEPT9 SNAI1 TBXAS1 TPPP3 XDH
PSMA4 RECQL SERPINA1 SNAI2 TCEB2 TPSAB1 XIAP
PSMA7 RECQL4 SERPINA3 SNCA TCF3 TRAF1 XPC
PSMB5 RECQL5 SERPINA6 SNCAIP TCF4 TRAF2 XRCC4
PSMB7 REL SERPINA7 SNIP1 TCF7L2 TRAF3 XRCC5
PSMB8 RELB SERPINB3 SNRNP70 TCL1A TRAF3IP2 XRCC6
PSMC1 RERE SERPINB4 SNX6 TCP1 TRAF6 YAP1
PSMC4 RET SERPINB5 SOAT1 TEAD1 TREH YARS
PSMC5 REXO2 SERPINC1 SOAT2 TEAD4 TRH YBX1
PSMC6 RFC2 SERPINE1 SOCS1 TEC TRIM21 YME1L1
PSMD10 RFC3 SERPINF1 SOCS3 TENC1 TRIM24 YWHAB
PSMD13 RFWD2 SERPINF2 SOD1 TERF1 TRIM63 YWHAE
PSMD4 RFX1 SERPING1 SOD2 TERT TRPC3 YWHAG
PSMD9 RFXANK SERPINI2 SOD3 TES TRPC4 YWHAH
PSME1 RGS2 SET SORBS3 TF TRPC6 YWHAQ
PSME3 RGS3 SETDB1 SORT1 TFAM TRPM1 YWHAZ
PSRC1 RGS4 SFN SOS1 TFAP2A TRPM2 YY1
PTBP1 RGS9 SFRP1 SOX5 TFAP2B TRPM4 ZAP70
PTCH1 RHOA SFTPA1 SP1 TFAP2C TRPV4 ZBTB16
PTEN RHOB SFTPC SP100 TFDP1 TSC1 ZEB1
PTGDR RHOC SFTPD SP3 TFR2 TSC2 ZFHX3
PTGDS RHOD SGCB SP7 TFRC TSC22D3 ZFP36
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POSTN PTGER1 RHOH SGK1 SPAG9 TG TSG101 ZFPM1
POT1 PTGER2 RIPK1 SGOL1 SPARC TGFA TSHB ZFR
POU1F1 PTGER3 RIPK2 SH2D1A SPHK1 TGFB1 TSHR ZFYVE9
POU2AF1 PTGER4 RIPK3 SH3D19 SPI1 TGFB1I1 TSPAN7 ZMYND11
POU2F1 PTGES RLN1 SH3GLB1 SPINK1 TGFB2 TSPAN8 ZNF148
POU2F2 PTGES2 RNASE1 SHC1 SPINK5 TGFB3 TSPO ZNF217
POU4F1 PTGFR RNASEL SHOX SPINLW1 TGFBI TSPYL2 ZNF384
POU5F1 PTGIR RNF123 SIAH1 SPINT1 TGFBR1 TTC4
PPA1 PTGIS RNF128 SIAH2 SPINT2 TGFBR2 TTR
PPAP2A PTGS1 RNF135 SIK1 SPP1 TGFBR3 TUBA1B
PPARA PTGS2 RNF14 SIN3A SPTAN1 TGIF1 TUBA4A
PPARD PTH RNF19A SIRT1 SPTBN1 TGM1 TUBB
PPARG PTH1R RNF34 SIRT2 SPTLC1 TGM2 TUBG1
PPARGC1A PTHLH RNH1 SIT1 SPTLC2 TH TWIST1
PPARGC1B PTK2 ROBO1 SIVA1 SQSTM1 THBS1 TXN
PPBP PTK2B ROCK1 SKI SRA1 THOC1 TXNRD1
PPIA PTK7 ROCK2 SKP2 SRC THPO TXNRD2
PPID PTP4A3 RORA SLAMF6 SRD5A1 THRA TYMS
PPIG PTPN1 RPA1 SLC11A2 SREBF1 THRB TYR
PPM1A PTPN11 RPL11 SLC13A2 SREBF2 TIAF1 TYRP1
PPM1D PTPN12 RPN2 SLC16A1 SRF TIMP1 UAP1
PPP1CA PTPN2 RPS20 SLC17A5 SRPK1 TIMP3 UBASH3B
PPP1R13L PTPN3 RPS24 SLC19A1 SS18 TIRAP UBC
PPP1R15B PTPN6 RPS4X SLC1A1 SSB TJP1 UBE2C
PPP1R2 PTPN7 RPS6KA1 SLC1A2 SST TJP2 UBE2E1
PPP1R8 PTPRB RPS6KA3 SLC1A3 SSTR1 TK1 UBE2K
PPP1R9B PTPRC RPS6KB1 SLC22A1 ST3GAL5 TKT UBE2N
PPP2CA PTPRO RRAS SLC22A12 ST5 TLE1 UBE3A
PPP2R2B PTPRZ1 RRBP1 SLC22A18 ST7 TLK1 UBQLN1
PPP2R4 PTS RRM1 SLC22A2 ST7L TLN1 UCHL1
PPP3CA PUF60 RRM2 SLC22A7 ST8SIA1 TLR1 UCN
PPP5C PVR RSF1 SLC25A13 STAT1 TLR2 UCP1
PPY PVRL2 RTN4 SLC25A14 STAT2 TLR3 UCP2
PQBP1 PXK RUFY3 SLC25A22 STAT3 TLR4 UCP3
PRDM1 PXN RUNX1 SLC25A27 STAT4 TLR9 UHRF1
PRDM10 PYGB RUNX1T1 SLC25A4 STAT5A TMEFF2 UNG
PRDM2 PYY RUNX2 SLC25A5 STAT5B TMPO UPF3A
PRDX1 QSOX1 RUNX3 SLC26A4 STAT6 TMPRSS11A USF1
PRDX2 RAB11FIP1 RXRA SLC27A2 STAU1 TMPRSS2 USF2
PRDX4 RAB1A RXRB SLC29A1 STIM1 TNC USP2
PRDX5 RABAC1 RXRG SLC2A1 STK11 TNF USP4
PRDX6 RAC1 RYR1 SLC2A2 STK17B TNFAIP3 USP5
PRKAA1 RAC2 RYR2 SLC2A4 STK36 TNFRSF10A USP7
PRKAA2 RAD1 S100A1 SLC30A9 STMN1 TNFRSF10B UTRN
PRKAB1 RAD51 S100A6 SLC35C1 STMN2 TNFRSF11A UTS2
PRKACA RAD52 S100A7 SLC39A4 STS TNFRSF11B UXT
PRKAR1A RAET1E S100B SLC3A2 STT3A TNFRSF13C VAV1
PRKAR2A RAF1 S1PR1 SLC4A1 STT3B TNFRSF18 VAV2
PRKAR2B RALA S1PR2 SLC4A2 STX11 TNFRSF1A VAV3
PRKCA RAMP2 SAA4 SLC4A4 STX1A TNFRSF1B VCAM1
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APPENDIX B: GeneChip exon array: probe set intensity plots
ATM (c hrll) 
14~----------------~----~~==========~ 
stimulated 
6 ----.. .. ---- -- -------- . --- -
4 ----- -- .... -.-.------------- ... --------- ------ .----.-------- -----.--.-.---------------
2 ----- --- --.--.-. --- -- -- -- -- -- --- -.- -- -- -- -- -- --. -.-.. -.- -- -- -- -- -- -- -------.- -- -- -- -- -- -- .--- --- ---
O ~======================================~ ENST00000452508 ~ 1 
~~==============================~ ENST00000278616 ~ 1 
~================================~ 
ENST00000389511 t 1 
~================================~ 
ENST00000299392 t 1 
~================================~ ENST00000419286~t __________________________________________ _J1 
vel (chrl O) 
14 ~------------------~--~--~==========~ 
12 
10 
8 
6 
stimulated 
inhibited 
O ~======================================~ 
ENST00000436396t 1 
ENST00000211998~t::!:~~~~~~~~~~~~~~~~~~~~1 
ENST00000417648t 1 
ENST00000372755Et::~~~~~~~~~~~~~~~~::~~~~1 ENST00000415462[ 1 
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MXII (chrlO) 
14r-------------------~--~~==========~ 
12 
10 
8 -· 
6 
4 _.... , ..... .... , .... , .......... . 
stimulated 
- - inhibited 
ENST0000033267~~E============================================~3 
ENST00000239oo7~E============================================~3 ENST00000442296~E============================================~3 
ENST00000369614~E============================================~3 ENST00000453116~E============================================~3 ENST00000369612~E============================================~3 
ENST00000369613~E============================================~3 ENST00000393134~E============================================~3 ENST00000361248~E============================================~3 
ENST00000369623 ~E ===========================~3 ENST00000369619 ~E ____________________________________________ ~3 
lO~ ______ ;r ________ C_A_L_D_l~(:C_h_r7~)~~============~ 
9 
8 .. 
7 
6 . . 
S 
4 
3 
2 
stimulated 
ENST0000042492~~F====================================~========~3 
ENST0000044SS69~F==============================================~3 ENST00000436461~F==============================================~3 ENST00000432646~F==============================================~3 ENST000004S4108~E==============================================~3 ENST00000361388~E==============================================~3 ENST00000417172~F==============================================~3 ENST00000393118~F==============================================~3 ENST0000043008S~F==============================================~3 ENST00000361901~E==============================================~3 ENST00000422748~F==============================================~3 ENST00000435928~F==============================================~3 ENST00000361675~F==============================================~3 ENST00000443197LF ______________________________________________ ~3 
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NRPI (chrlO) 
11~------------------------------------------~ 
10 _. --._- ._- .-- .- .... -.. -.. -.. -_. -- -..... -_. ----- ._- ._- ... -.. - . _ .. --.--
9 
8 
7 
6 
5 
4 
3 
ENST0000026537f FE =======================l3 
ENST00000374818~F=====================~3 ENST00000374816~E=====================~3 
ENST00000418675 FE = ======= ===============l3 ENST00000374814FF==========================================~3 ENST00000374867FF==========================================~3 ENST00000374875 ~F ==========================================~3 ENST00000395995~E==========================================~3 ENST00000431894~E==========================================~3 ENST00000374823~E==========================================~3 ENST00000413802FE==========================================~3 ENST00000374821FE==========================================~3 ENST00000374833FE==========================================~3 ENST00000455749FE==========================================~3 ENST00000374828FF==========================================~3 ENST00000432372~F==========================================~3 ENST00000374822~F __________________________________________ ~3 
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APPENDIX C: Ensembl protein sequences
LCK-202
MGYYNGHTKVAVKSLKQGSMSPDAFLAEANLMKQLQHQRLVRLYAVVTQEPIYIITEYMENGSLVDFLKTPSG
IKLTINKLLDMAAQIAEGMAFIEERNYIHRDLRAANILVSDTLSCKIADFGLARLIEDNEYTAREGAKFPIKWTAP
EAINYGTFTIKSDVWSFGILLTEIVTHGRIPYPGMTNPEVIQNLERGYRMVRPDNCPEELYQLMRLCWKERPED
RPTFDYLRSVLEDFFTATEGQYQPQP
LCK-006
MGCGCSSHPEDDWMENIDVCENCHYPIVPLDGKGTLLIRNGSEVRDPLVTYEGSNPPASPLQDNLVIALHSYEP
SHDGDLGFEKGEQLRILEQSGEWWKAQSLTTGQEGFIPFNFVAKANSLEPEPWFFKNLSRKDAERQLLAPGNT
HGSFLIRESESTAGSFSLSVRDFDQNQGEVVKHYKIRNLDNGGFYISPRITFPGLHELVRHYTRYYNGHTKVAVK
SLKQGSMSPDAFLAEANLMKQLQHQRLVRLYAVVTQEPIYIITEYMENGSLVDFLKTPSGIKLTINKLLDMAAQI
AEGMAFIEERNYIHRDLRAANI
LCK-010
MGIPGSHNLRYFWNFPGQGPIISDVGGADLGGAPSAPSSIPSGTMGCGCSSHPEDDWMENIDVCENCHYPIVPLD
GKGTLLIRNGSEVRDPLVTYEGSNPPASPLQDNLVIALHSYEPSHDGDLGFEKGEQLRILEQSGEWWKAQSLTTGQEGFI
PFNFVAKANSLEPEPWFFKNLSRKDAERQLLAPGNTHGSFLIRESESTAGSFSLSVRDFDQNQGEVVKHYKIRNLDNGGF
YISPRITFPGLHELVRHYTNASDGLCTRLSRPCQTQKPQKPWWEDEWEVP
VCL-001
MPVFHTRTIESILEPVAQQISHLVIMHEEGEVDGKAIPDLTAPVAAVQAAVSNLVRVGKETVQTTEDQILKRDMPPA
FIKVENACTKLVQAAQMLQSDPYSVPARDYLIDGSRGILSGTSDLLLTFDEAEVRKIIRVCKGILEYLTVAEVVETMEDL
VTYTKNLGPGMTKMAKMIDERQQELTHQEHRVMLVNSMNTVKELLPVLISAMKIFVTTKNSKNQGIEEALKNRNFTVEKM
SAEINEIIRVLQLTSWDEDAWASKDTEAMKRALASIDSKLNQAKGWLRDPSASPGDAGEQAIRQILDEAGKVGELCAGKE
RREILGTCKMLGQMTDQVADLRARGQGSSPVAMQKAQQVSQGLDVLTAKVENAARKLEAMTNSKQSIAKKIDAAQNWLAD
PNGGPEGEEQIRGALAEARKIAELCDDPKERDDILRSLGEISALTSKLADLRRQGKGDSPEARALAKQVATALQNLQTKT
NRAVANSRPAKAAVHLEGKIEQAQRWIDNPTVDDRGVGQAAIRGLVAEGHRLANVMMGPYRQDLLAKCDRVDQLTAQLAD
LAARGEGESPQARALASQLQDSLKDLKARMQEAMTQEVSDVFSDTTTPIKLLAVAATAPPDAPNREEVFDERAANFENHS
GKLGATAEKAAAVGTANKSTVEGIQASVKTARELTPQVVSAARILLRNPGNQAAYEHFETMKNQWIDNVEKMTGLVDEAI
DTKSLLDASEEAIKKDLDKCKVAMANIQPQMLVAGATSIARRANRILLVAKREVENSEDPKFREAVKAASDELSKTISPM
VMDAKAVAGNISDPGLQKSFLDSGYRILGAVAKVREAFQPQEPDFPPPPPDLEQLRLTDELAPPKPPLPEGEVPPPRPPP
PEEKDEEFPEQKAGEVINQPMMMAARQLHDEARKWSSKGNDIIAAAKRMALLMAEMSRLVRGGSGTKRALIQCAKDIAKA
SDEVTRLAKEVAKQCTDKRIRTNLLQVCERIPTISTQLKILSTVKATMLGRTNISDEESEQATEMLVHNAQNLMQSVKET
VREAEAASIKIRTDAGFTLRWVRKTPWYQ
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VCL-202
MLQSDPYSVPARDYLIDGSRGILSGTSDLLLTFDEAEVRKIIRVCKGILEYLTVAEVVETMEDLVTYTKNLGPGMTK
MAKMIDERQQELTHQEHRVMLVNSMNTVKELLPVLISAMKIFVTTKNSKNQGIEEALKNRNFTVEKMSAEINEIIRVLQL
TSWDEDAWASKDTEAMKRALASIDSKLNQAKGWLRDPSASPGDAGEQAIRQILDEAGKVGELCAGKERREILGTCKMLGQ
MTDQVADLRARGQGSSPVAMQKAQQVSQGLDVLTAKVENAARKLEAMTNSKQSIAKKIDAAQNWLADPNGGPEGEEQIRG
ALAEARKIAELCDDPKERDDILRSLGEISALTSKLADLRRQGKGDSPEARALAKQVATALQNLQTKTNRAVANSRPAKAA
VHLEGKIEQAQRWIDNPTVDDRGVGQAAIRGLVAEGHRLANVMMGPYRQDLLAKCDRVDQLTAQLADLAARGEGESPQAR
ALASQLQDSLKDLKARMQEAMTQEVSDVFSDTTTPIKLLAVAATAPPDAPNREEVFDERAANFENHSGKLGATAEKAAAV
GTANKSTVEGIQASVKTARELTPQVVSAARILLRNPGNQAAYEHFETMKNQWIDNVEKMTGLVDEAIDTKSLLDASEEAI
KKDLDKCKVAMANIQPQMLVAGATSIARRANRILLVAKREVENSEDPKFREAVKAASDELSKTISPMVMDAKAVAGNISD
PGLQKSFLDSGYRILGAVAKVREAFQPQEPDFPPPPPDLEQLRLTDELAPPKPPLPEGEVPPPRPPPPEEKDEEFPEQKA
GEVINQPMMMAARQLHDEARKWSSKPGIPAAEVGIGVVAEADAADAAGFPVPPDMEDDYEPELLLMPSNQPVNQPILAAA
QSLHREATKWSSKGNDIIAAAKRMALLMAEMSRLVRGGSVPRTSPRPQMR
VCL-204
MPPAFIKVENACTKLVQAAQMLQSDPYSVPARDYLIDGSRGILSGTSDLLLTFDEAEVRKIIRVCKGILEYLTVA
EVVETMEDLVTYTKNLGPGMTKMAKMIDERQQELTHQEHRVMLVNSMNTVKELLPVLISAMKIFVTTKNSKNQGIEEALK
NRNFTVEKMSAEINEIIRVLQLTSWDEDAWASKDTEAMKRALASIDSKLNQAKGWLRDPSASPGDAGEQAIRQILDEAGK
VGELCAGKERREILGTCKMLGQMTDQVADLRARGQGSSPVAMQKAQQVSQGLDVLTAKVENAARKLEAMTNSKQSIAKKI
DAAQNWLADPNGGPEGEEQIRGALAEARKIAELCDDPKERDDILRSLGEISALTSKLADLRRQGKGDSPEARALAKQVAT
ALQNLQTKTNRAVANSRPAKAAVHLEGKIEQAQRWIDNPTVDDRGVGQAAIRGLVAEGHRLANVMMGPYRQDLLAKCDRV
DQLTAQLADLAARGEGESPQARALASQLQDSLKDLKARMQEAMTQEVSDVFSDTTTPIKLLAVAATAPPDAPNREEVFDE
RAANFENHSGKLGATAEKAAAVGTANKSTVEGIQASVKTARELTPQVVSAARILLRNPGNQAAYEHFETMKNQWIDNVEK
MTGLVDEAIDTKSLLDASEEAIKKDLDKCKVAMANIQPQMLVAGATSIARRANRILLVAKREVENSEDPKFREAVKAASD
ELSKTISPMVMDAKAVAGNISDPGLQKSFLDSGYRILGAVAKVREAFQPQEPDFPPPPPDLEQLRLTDELAPPKPPLPEG
EVPPPRPPPPEEKDEEFPEQKAGEVINQPMMMAARQLHDEARKWSSKGNDIIAAAKRMALLMAEMSRLVRGGSGTKRALI
QCAKDIAKASDEVTRLAKEVAKQCTDKRIRTNLLQVCERIPTISTQLKILSTVKATMLGRTNISDEESEQATEMLVHNAQ
NLMQSVKETVRELKLLQSKFEQMLDLHCAGLERLPGTSRHLAEPGWHRNLY
NRP1-001
MERGLPLLCAVLALVLAPAGAFRNDKCGDTIKIESPGYLTSPGYPHSYHPSEKCEWLIQAPDPYQRIMINFNPHFD
LEDRDCKYDYVEVFDGENENGHFRGKFCGKIAPPPVVSSGPFLFIKFVSDYETHGAGFSIRYEIFKRGPECSQNYTTPSG
VIKSPGFPEKYPNSLECTYIVFVPKMSEIILEFESFDLEPDSNPPGGMFCRYDRLEIWDGFPDVGPHIGRYCGQKTPGRI
RSSSGILSMVFYTDSAIAKEGFSANYSVLQSSVSEDFKCMEALGMESGEIHSDQITASSQYSTNWSAERSRLNYPENGWT
PGEDSYREWIQVDLGLLRFVTAVGTQGAISKETKKKYYVKTYKIDVSSNGEDWITIKEGNKPVLFQGNTNPTDVVVAVFP
KPLITRFVRIKPATWETGISMRFEVYGCKITDYPCSGMLGMVSGLISDSQITSSNQGDRNWMPENIRLVTSRSGWALPPA
PHSYINEWLQIDLGEEKIVRGIIIQGGKHRENKVFMRKFKIGYSNNGSDWKMIMDDSKRKAKSFEGNNNYDTPELRTFPA
LSTRFIRIYPERATHGGLGLRMELLGCEVEAPTAGPTTPNGNLVDECDDDQANCHSGTGDDFQLTGGTTVLATEKPTVID
STIQSEFPTYGFNCEFGWGSHKTFCHWEHDNHVQLKWSVLTSKTGPIQDHTGDGNFIYSQADENQKGKVARLVSPVVYSQ
NSAHCMTFWYHMSGSHVGTLRVKLRYQKPEEYDQLVWMAIGHQGDHWKEGRVLLHKSLKLYQVIFEGEIGKGNLGGIAVD
DISINNHISQEDCAKPADLDKKNPEIKIDETGSTPGYEGEGEGDKNISRKPGNVLKTLDPILITIIAMSALGVLLGAVCG
VVLYCACWHNGMSERNLSALENYNFELVDGVKLKKDKLNTQSTYSEA
NRP1-201
MDDSKRKAKSFEGNNNYDTPELRTFPALSTRFIRIYPERATHGGLGLRMELLGCEVEAPTAGPTTPNGNLVDECDD
DQANCHSGTGDDFQLTGGTTVLATEKPTVIDSTIQSGSRFFKHHHKQQSMRPQNLHHNSILLL
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PRMT5-006
XIRPETHSPGMFSWFPILFPIKQPITVREGQTICVRFWRCSNSKKGSSHQSMKTSGQGVRN
PRMT5-017
SQLEVQFIITGTNHHSEKEFCSYLQYLEYLSQNRPPPNAYELFAKGYEDYLQSPLQPLMDNLESQTYEVFEKDPIK
YSQYQQAIYKCLLDRVPEEEKDTNVQVLMVLGAGRGPLVNASLRAAKQADRRIKLLENWQFE
PRMT5-020
RRNSEAAMLQELNFGAYLGLPAFLLPLNQEDNTNLARVLTNHIHTGHHSSMFWMRVPLVAPEDLRDDIIENAPTTHTEEY
SGEEKTWMWWHNFRTLCDYTLEIGADLPSNHVIDRWLGEPIKAAILPTSIFLTNKKGFPVLSKMHQRLIFRLLKLEVQFI
ITGTNHHSEKEFCSYLQYLEYLSQNRPPPNAYELFAKGYEDYLQSPLQPLMDNLESQTYEVFEKDPIKYSQYQQAIYKCL
LDRVPEEEKDTNVQVLMVLGAGRGPLVNASLRAAKQADR
PRMT5-018
MHQRLIFRLLKLEVQFIITGTNHHSEKEFCSYLQYLEYLSQNRPPPNAYELFAKGYEDYLQSPLQPLMDNLESQTYEVFE
KDPIKYSQYQQAIYKCLLDRVPEE
PRMT5-014
MAAMAVGGAGGSRVSSGRDLNCVPEIADTLGAVAKQGFDFLCMPVFHPRFKREFIQEPAKNRPGPQTRSDLLLSGRDWNT
LIVGKLSPWIRPDSKVEKIRRNSEALEVQFIITGTNHHSEKEFCSYLQYLEYLSQNRPPPNAYELFAKGYEDYLQSPLQP
LMDNLESQTYEVFEKDPIKYSQY
